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MARIJUANA USE, HEAVY DRINKING, AND COGNITIVE DYSFUNCTION IN 
PEOPLE WITH HUMAN IMMUNODEFICIENCY VIRUS -INFECTION 
SARA LORKIEWICZ 
ABSTRACT 
 
Aims: Substance use and dependence is very common among people living with HIV-
infection. Since substances like alcohol and marijuana as well as the HIV virus itself are 
believed to have negative effects on cognition and the brain, our aim was to test the 
hypothesis that current and lifetime marijuana and heavy alcohol use are associated with 
cognitive dysfunction in people with HIV-infection.  
 
Methods: Boston ARCH cohort participants consisted of 215 HIV-infected adults with 
substance dependence or current or past injection drug use. In cross-sectional, regression 
analyses we tested the association between current marijuana use (number of days 
marijuana was used in the past 30 days), current heavy alcohol use (number of heavy 
drinking days in the past 30 days defined as ≥4 drinks for women and ≥ 5 for men in 24 
hours), lifetime marijuana use (number of years marijuana was used ≥ 3 times per week), 
lifetime alcohol use (total Kg), duration of heavy alcohol use (# of years alcohol was use 
> 84 grams or > 6 drinks per day), and three measures of cognitive dysfunction: i) 
memory and ii) attention domains of the Montreal Cognitive Assessment (MoCA), and 
iii) 4-item cognitive function scale (CF4) from the Medical Outcomes Study HIV Health 
Survey (MOS-HIV, range 0-100). Eight multivariable models were fit comparing: 1. 
current marijuana use by each cognitive outcome, 2. current heavy alcohol use by each 
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cognitive outcome, 3. lifetime marijuana use by each cognitive outcome, 4. lifetime 
alcohol use (Kg) by each cognitive outcome, 5. lifetime marijuana use, duration of heavy 
alcohol use, current heavy alcohol use, and current marijuana use by each cognitive 
outcome, 6. lifetime marijuana use, lifetime alcohol use (Kg), current heavy alcohol use, 
and current marijuana use by each cognitive outcome, 7. the interaction between current 
marijuana and heavy alcohol use by each cognitive outcome, and 8. the interaction 
between lifetime marijuana and lifetime alcohol use (Kg) by each cognitive outcome. 
Analyses were adjusted for demographics, primary language, comorbidities, depressive 
symptoms, anxiety, antiretroviral therapy, HIV-viral load, CD4 count, lifetime cocaine 
use, cocaine use in the past 30 days, illicit opioid use in the past 30 days, and any 
prescribed opioids.  
 
Results: Participant characteristics were as follows: Mean age 49 yrs., 35% female, 20% 
white, 66% ≥ 12 years of education, 86% English as primary language, 82% unemployed, 
mean Charlson comorbidity score 2.9, 28% scored ≥ 3 on the PHQ-2 indicating 
depressive symptoms, 44% scored ≥ 8 on OASIS indicating symptoms of anxiety, 58% 
had Hepatitis C infection at some point in their life, 86% were on HAART, 72% had an 
HIV-viral load < 200 copies/mL, CD4 cell count/mm3 was 10% <200 and 33% 200 - 
<500, mean HIV duration was 16 years, lifetime cocaine use was 9 years, 30% used 
cocaine in the past 30 days, 25% used illicit opioids in the past 30 days, and 61% were 
prescribed opioids. Current marijuana use was significantly associated with a lower 
MOS-HIV CF4 score in three of the fully adjusted models (1,5, and 6) listed previously 
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with a decrease in 0.30 points for every day of use, but neither MoCA score. Current 
heavy alcohol use was also associated with a higher MOS-HIV CF4 score in model 5, 
increasing 0.36 points for every day of use. This finding did not confirm our hypothesis 
and in fact was opposite our projections. Lifetime marijuana use and lifetime alcohol use 
were not associated with any measure of cognitive dysfunction, and there was no 
interaction between lifetime marijuana use and lifetime alcohol use with cognitive 
dysfunction, and no interaction between current marijuana use and current alcohol use 
with cognitive dysfunction.  
 
Conclusion: Current marijuana use may be associated with cognitive dysfunction. We 
also detected an unexpected association between current heavy alcohol use and better 
cognitive function, but it is not biologically plausible. However, we did not detect 
associations between lifetime alcohol or marijuana use and cognitive dysfunction among 
people with substance dependence and HIV-infection. Further research, particularly on 
long-term exposure to substances, should include subtler measures of cognitive 
dysfunction and consider whether or not cognitive dysfunction that may be the 
consequence of marijuana and alcohol use is detectable among those who have many 
other factors effecting cognition. These results suggest that marijuana use should not be 
considered benign for individuals with substance dependence and HIV-infection.  
 
 
 
 
 
viii 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
ACKNOWLEDGMENTS ................................................................................................. iv 
ABSTRACT ........................................................................................................................ v 
TABLE OF CONTENTS ................................................................................................. viii 
LIST OF TABLES ............................................................................................................. xi 
LIST OF FIGURES .......................................................................................................... xii 
LIST OF ABBREVIATIONS .......................................................................................... xiii 
INTRODUCTION .............................................................................................................. 1 
Effects of the HIV Virus on the Brain and Cognition ..................................................... 1 
Effects of Marijuana Use, Alcohol Use, and Their Interaction with HIV on the Brain 
and Cognition .................................................................................................................. 6 
Effects of Marijuana Use on the Brian and Cognition ................................................ 7 
Acute Effects of Marijuana Use on the Brain and Cognition ..................................... 8 
Residual Effects of Marijuana Use on Cognitive Function ...................................... 10 
Marijuana Withdrawal .............................................................................................. 11 
Long-Term, Persistent Effects of Marijuana Use on Cognitive Function ................ 12 
Effects of Long-Term Marijuana Use on the Brain .................................................. 13 
Marijuana and HIV ................................................................................................... 14 
 
 
ix 
Effects of Alcohol Use on the Brain and Cognition ................................................. 16 
Effects of Acute Alcohol Use on Cognition ............................................................. 18 
Effects of Chronic Alcohol Use on Cognition .......................................................... 20 
The Effects of Alcohol on Cognition can be Reversible .......................................... 21 
Alcohol and HIV ....................................................................................................... 22 
SPECIFIC AIMS .............................................................................................................. 25 
METHODS ....................................................................................................................... 27 
Design and Human Subjects Approval ......................................................................... 27 
Sample ........................................................................................................................... 27 
Data Collection .............................................................................................................. 28 
Independent Variables ................................................................................................... 29 
Dependent Variables ..................................................................................................... 31 
Analysis ......................................................................................................................... 34 
RESULTS ......................................................................................................................... 38 
Descriptive Statistics ..................................................................................................... 38 
Demographics ........................................................................................................... 38 
Main Independent Variables ..................................................................................... 41 
Dependent Variables ................................................................................................. 46 
Results of Regression analyses ................................................................................. 47 
DISCUSSION ................................................................................................................... 54 
CONCLUSION ................................................................................................................. 59 
APPENDIX A ................................................................................................................... 60 
APPENDIX B ................................................................................................................... 61 
 
 
x 
APPENDIX C ................................................................................................................... 62 
APPENDIX D ................................................................................................................... 63 
APPENDIX E ................................................................................................................... 70 
APPENDIX F.................................................................................................................... 72 
LIST OF JOURNAL ABBREVIATIONS........................................................................ 74 
REFERENCES ................................................................................................................. 77 
CURRICULUM VITAE ................................................................................................... 87 
 
 
 
  
 
 
xi 
LIST OF TABLES 
 
Table     Title              Page 
 
1 Descriptive Statistics for Independent Variables, Dependent  
Variables and Covariates      39-40 
 
2 Bivariate Analysis        41-42 
 
3 Significant Association Between Current Marijuana Use and  
MOS-HIV CF4 Score       47 
 
4 No Association Between Current Heavy Drinking and  
Cognitive Outcomes       48 
 
5 No Association Between Lifetime Marijuana Use and  
Cognitive Outcomes       49 
 
6 No Association Between Lifetime Alcohol Use (Kg) and 
Cognitive Outcomes       50 
 
7 Significant Associations Between Current Marijuana, Heavy 
Alcohol Use (Kg), and MOS-HIV CF4 Score   51 
 
8 Significant Association Between Current Marijuana Use and 
MOS-HIV CF4 Score       52 
 
 
 
 
  
 
 
xii 
LIST OF FIGURES 
 
Table Title Page 
1 Independent and Dependent Variables used in Analyses 33 
2 Multivariable Linear and Logistic Regression Models 37 
3 Distributions for Current Marijuana and Heavy 
 Alcohol Use 
        44 
4 Distributions for Lifetime Marijuana and Heavy  
Alcohol Use 
45 
5 Distributions and Frequencies for Dependent Variables  
 
46 
 
 
 
 
 
 
 
 
  
 
 
xiii 
LIST OF ABBREVIATIONS 
 
ANI…………………………………...Asymptomatic Neurocognitive Impairment        
ARD……………………………………………………Alcohol Related Dementia 
ASI…………………………………………………..…..Addiction Severity Index 
ATP ……………………………………………………..Adenosine Triphosphate  
BBB……………………………………………………………Blood Brain Barrier 
CBF…………………………………………………………..Cerebral Blood Flow 
CNS……………………………………………………….Central Nervous System  
CSF……………………………………………………………Cerebrospinal Fluid 
DSM-5 ………………….Diagnostic and Statistical Manual of Mental Disorders  
DTI …………………………….……………………….Diffusion Tensor Imaging 
ELISA……………………………………..Enzyme Linked Immunosorbent Assay 
HAART…………………………………...Highly Active Anti-Retroviral Therapy 
HANDs……………………………….HIV-Associated Neurocognitive Disorders 
HCV……………………………………………………………...Hepatitis C Virus 
HIV………………………………………………Human Immunodeficiency Virus  
HIV-D…………………………..…………………………...HIV-related dementia 
MCP-1…………………………...………….Monocyte Chemoattractant Protein-1 
MND………………………………………………..Minor Neurocognitive Deficit 
MoCA…………………………………………….Montreal Cognitive Assessment 
MOS-HIV CF4……….…………….Medical Outcomes Study HIV Health Survey  
Cognitive Function (4 Questions) 
 
 
xiv 
 
MRI ………………………………………………...Magnetic Resonance Imaging  
MRS …………………………………………..Magnetic Resonance Spectroscopy 
NAA…………………………………………………………..N-Acetyl Aspartate  
NMDA……………………………………………………N-Methyl-D-Aspartate 
OASIS …………………………Overall Anxiety Severity and Impairment Scale  
PCr ……………………………………………………..…………Phosphocreatine  
PDE  ……………………………………………………………Phosphodiesterase  
PHQ-2……………………………………………...Patient Health Questionnaire 2 
rCBF……………………………………………….Regional Cerebral Blood Flow 
TLFB………………………………………………………..Timeline Follow Back  
WKS………………………………………………Wernicke-Korsakoff Syndrome 
∆9-THC…………………………..…………………Delta-9-Tetrahydrocannabinol  
≥…………………………………...………………………Greater than or equal to  
>……………………………………………………………………….Greater than  
<……………………………………………....………………………….Less Than  
 
 
 
 
 
 
1 
INTRODUCTION 
 
The prevalence of people living with the human immunodeficiency virus (HIV) is 
estimated to be around 1.2 million people in the United States and 35 million people 
worldwide91,92. With the advent of highly active anti-retroviral therapy (HAART), 
individuals with HIV are living longer, healthier lives than they have in the past. Despite 
overall improvements in HIV viral load, CD4 cell counts, symptomology, and general 
suppression of the virus in the periphery in those treated with HAART, cognitive effects 
of the virus can still be observed, in part due to continued infection of the central nervous 
system (CNS)2,10. At the same time, use of and dependence on substances such as alcohol 
and marijuana is particularly high in HIV-infected people despite documented effects of 
both on cognition19. Since the HIV virus, alcohol, and marijuana all have potential 
deleterious effects on the brain and cognition, it is important to determine whether there 
is a negative, synergistic effect of all three. Cognitive dysfunction lowers an individual’s 
quality of life and can hinder one’s ability to maintain the complicated medication 
regimens required to suppress HIV-infection. This can ultimately increase the risk for 
worse disease outcomes and higher rates of mortality.  
 
Effects of the HIV Virus on the Brain and Cognition   
The brain is believed to serve as a reservoir for the HIV virus, entering the central 
nervous system (CNS) via a “Trojan horse” mechanism early on in infection4,5,7. The 
virus is able to cross the blood brain barrier (BBB) undetected in immature monocytes 
 
 
2 
and lymphocytes, which then become activated in the brain with the ability to spread the 
virus and induce neuronal injury4,5,7. HIV can infect microglia and astrocytes in the 
CNS.7 Microglia are the main reservoirs for the virus, while astrocytes are infected to a 
lesser extent.7 Neurons have not been found to harbor the virus7. Neuronal damage due to 
HIV-infection can be caused directly by the virus or indirectly through activation of the 
innate immune system. Infected lymphocytes and macrophages release neurotoxic and 
pro-inflammatory chemicals causing astrocytosis, neuronal injury, and inflammation4,5,7. 
Astrocytosis increases the permeability of the BBB, which may cause further propagation 
of infection into the brain4,5,7. Neuronal injury is worsened by the release of glutamate 
and oxidative stress which is induced by neurotoxic chemokines and inflammation4,5,7. 
The HIV viral envelope protein, gp120, is also known to inhibit neuronal growth and 
induce apoptosis of neurons13. In both direct and indirect brain injury, damage to the 
dendrites and synapses of neurons appears to be more detrimental to cognitive function 
than the loss of neurons11. It is thought that complement, a main player of the innate 
immune system, plays a role in the indirect damage of neural tissue8. Neurons are known 
to be particularly susceptible to the membrane attack complex (MAC), or end result of 
the complement cascade, which induces apoptosis in cells8. While levels of complement 
in the CNS are normally very low, they are found to be elevated in individuals with HIV8. 
Complement regulatory factors are also shown to be downregulated in CNS tissue of 
those with HIV, which would cause an increased susceptibility to MAC8.  
The major site of HIV-infection in the brain appears to be the basal ganglia, as it 
normally contains the highest concentration of the virus1,9-11. However, HIV also has 
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effects on other subcortical gray matter structures, deep white matter tracts, and the 
frontal cortices1,9,11,20. There appears to be more gray than white matter involvement20. 
Pathophysiological signs of HIV-infection in the brain include myelin loss, giant, 
multinucleated cells (infected perivascular macrophages), gliosis, and microglial 
nodules4,9,11. Cerebral atrophy and a decreased resting cerebral blood flow (CBF) are the 
most salient alterations of HIV-infection to brain morphology and metabolism, both of 
which appear to worsen with disease progression7,10. Cardenas et al found that HIV-
infected people on HAART show a significantly greater loss of global white matter than 
those not infected with the virus and that a worse disease progression (lower CD4 cell 
counts and increased viral load) correlates with greater tissue loss10. There is also thought 
to be a decrease in N-acetyl aspartate (NAA), a marker of mature neurons and their 
processes, and an increase in choline and myoinositol, markers of cell membrane 
breakdown and inflammation respectively, in the brains of those with HIV-infection7. 
HIV-infection of the brain typically presents with a triad of behavioral, motor, and 
cognitive symptoms3,5,7,9,11. Eventually, behavior becomes apathetic and there is a 
decrease in spontaneity9. A loss of fine motor control is seen accompanied with postural 
instability and bradykinesia that resembles Parkinson’s disease without the resting 
tremor9. HIV affects a number of cognitive domains that are primarily associated with 
subcortical damage: learning and memory, attention, executive function, and language1,21. 
HIV-associated neurocognitive disorders (HANDs) are becoming the most 
common form of young-age dementia worldwide and are present in around 30% of 
individuals living with the virus1,7. HAND is a spectrum of organic neurocognitive 
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disorders induced by the HIV virus itself (excluding opportunistic infections of the brain, 
active drug use, and psychiatric disorders) ranging from mild impairment of cognition 
and daily functioning to debilitating dementia1,3-5. Generally, five major areas of 
cognitive function must be assessed when diagnosing HAND including: executive 
function, learning and memory, complex attention, language, and perceptual-motor 
function1,21. Since the onset of HAART, the most debilitating form of HAND, HIV-
associated dementia (HIV-D), has decreased in prevalence, but more mild forms still 
persist, with 27% of HIV-infected individuals with suppressed viral loads having 
cognitive complaints concerning memory, mental slowing, and attention1,7.  
HAND is thus a general term encompassing asymptomatic neurocognitive 
impairments (ANIs), mild neurocognitive deficits (MNDs) and HIV-D1,3-5. ANIs include 
cognitive deficits in at least two of the cognitive domains stated previously with no 
interference in everyday functioning1,3. It is believed that 21-30% of asymptomatic HIV- 
infected individuals are affected by ANIs as well as up to 50% of individuals diagnosed 
with HAND1. ANI can be considered a pre-symptomatic form of HAND7. MNDs include 
cognitive deficits in two domains of cognitive function with mild interference in daily 
functioning and a prevalence of 5-20% of HIV-infected people and 30-50% of 
individuals diagnosed with HAND1. HIV-D is defined as having deficits in two cognitive 
domains as well as marked interference in daily functioning with a prevalence of 1-2% of 
people living with HIV1. In general, HAND appears to be more prevalent in symptomatic 
individuals, regardless of whether they realize that cognitive impairments exist1. 
Likewise, any severity of HAND appears to be predictive of abnormal brain morphology, 
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a decrease in daily functioning, and early mortality1,6. Heaton et al found that those with 
neuropsychological impairments in executive function, attention, and working memory 
were more likely to fail laboratory simulated tests representative of medication 
management, financial management, and work assessment, revealing a potential decline 
in everyday functioning6.  
 HIV disease severity, age, vascular risk, cognitive reserve, Hepatitis C infection, 
and substance use disorders are all shown to worsen the progression of HAND13,17. 
Sacktor et al conducted a study looking at the additive effects of age and HAND on 
cognition in a cohort of older individuals. They found that older individuals with HIV-D 
tested worse in areas of executive function than their younger counterparts and that older 
individuals with MNDs tested worse in areas of executive function, memory, and motor 
speed than younger individuals14.  Foley et al extended the work of Sacktor et al, finding 
that cardiovascular disease, or “vascular risk,” is a predictor of cognitive dysfunction in 
the domain of processing speed and also interacts in a negative, additive way with age in 
the domain of verbal fluency15. In a study looking at whether high cognitive reserve may 
mask signs of neurodegeneration, Thames et al found that higher cognitive reserve was 
associated with greater atrophy in the basal ganglia despite similar levels of 
neurocognitive functioning across participants16. This means that individuals with a 
higher cognitive reserve won’t present with a form of HAND until they have greater 
brain damage.  
 Hepatitis C infection has become an important comorbidity to HIV-infection. The 
hepatitis C virus (HCV) has been shown to create cognitive impairment in its own right 
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in a similar subcortical fashion to HIV22. HCV is thought to cross the BBB after infection 
and individuals that are HCV positive were shown to have HCV antigens and antibodies 
present in the central nervous system, revealing that the brain is a site for viral replication 
of HCV as well18,19. It is plausible, then, that HCV augments the cognitive dysfunction 
and neuronal damage already induced by HIV. Letendre et al showed that 33% of 
individuals co-infected with HCV and HIV progressed to HIV-D and 62% showed signs 
of MND, which is a higher prevalence than that found in those infected with HIV alone18.  
 
Effects of Marijuana Use, Alcohol Use, and Their Interaction with HIV on the Brain 
and Cognition  
 Substance use and substance use disorders are extremely common in HIV-
infected individuals, with 40 – 74% of HIV-infected people reporting past or current 
substance use17. Half of people living with HIV/AIDS report the use of recreational 
marijuana and around one third report therapeutic marijuana use23. Likewise, individuals 
who use recreational marijuana have also been found more likely to drink alcohol23. 
Traditionally, alcohol use among HIV-infected people has been very high. Alcohol use 
and drinking at hazardous levels is around twice the prevalence in HIV-infected people 
than in that of the general population, with 37% of HIV-infected individuals drinking 
alcohol, and one third of those who drink doing so at hazardous levels24,25.  It is well 
documented that alcohol and marijuana effect cognitive function, and it is also believed 
that these substances can have a negative, additive effects on the brain when combined 
with HIV-infection.  
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Effects of Marijuana Use on the Brian and Cognition  
 Marijuana is arguably one of the most widely used illicit drugs in the United 
States and is thought by some laypersons to be a benign, recreational substance. Thus, it 
is important to understand what types of effects this drug may have on cognition and the 
brain.  The major psychoactive ingredient in marijuana is a cannabinoid by the name of 
delta-9-tetrahydrocannabinol (∆9-THC)26. ∆9-THC can cross the BBB where it binds to its 
primary CNS receptor, CB1, one of the most abundant receptors in the brain26. CB1 
receptors are found in highest concentration in the basal ganglia, cerebellum, and 
hippocampus26,27. In the hippocampus, marijuana can inhibit long-term potentiation, a 
process involved in memory formation26. Likewise, it can induce cell death in specific 
cells in the hippocampus during neuronal development26. CB1 receptors are also known 
to co-exist with dopamine receptors in the basal ganglia, and may inhibit dopamine action 
and thus have a potential effect on motor and psychomotor control26. ∆9-THC is stored in 
adipose tissue and has a long half-life because it can be slowly released into the system 
from these fat stores26.27. The psychoactive effects of marijuana begin after about 30 
minutes post ingestion and last for up to four hours27.  
 According to the Diagnostic and Statistical Manual of Mental Disorders (5th 
ed.; DSM–5; American Psychiatric Association, 2013), marijuana intoxication is shown 
to induce behavioral and psychological changes including impaired motor coordination, 
euphoria, anxiety, sensation of slowed time, impaired judgment, and social withdrawal. 
Individuals exposed to ∆9-THC report subjective increases in: relaxation, deep thought, 
sensory perception, laughter, dizziness, feeling withdrawn, hunger, paranoia, anxiety, 
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drowsiness, and depression27. Marijuana is thought to interfere with cognitive function in 
a temporal fashion, from the time of acute intoxication to what may be long after 
cessation of use. Thus, acute effects, residual effects, withdrawal effects, and long-term, 
persistent CNS effects of ∆9-THC have been observed.  Acute, residual, and long-term 
cognitive effects also appear to be dependent on whether or not marijuana is being used 
chronically and what concentration of ∆9-THC the individual is being exposed to. Users 
who have used marijuana the longest are thought to perform worse on cognitive tasks, 
and as the amount or potency of ∆9-THC increases during acute exposure, neurocognitive 
performance is also thought to decrease33,35,48,49.  
 
Acute Effects of Marijuana Use on the Brain and Cognition  
Acute effects of marijuana use are those occurring from the time of intoxication 
up to four hours afterward27. Acute marijuana use has been shown to alter brain 
metabolism, presumably leaving the brain’s architecture intact. Changes in cerebral blood 
flow (CBF) have been observed, most notably increases in the frontal, limbic, paralimbic, 
and cerebellar areas of the brain27. Correlations have been found between these regional 
CBF (rCBF) changes and the subjective feelings of intoxication reported by users of 
marijuana27.  For instance, increases in rCBF in the orbital/mesial frontal lobes and 
paralimbic areas are thought to be correlated with the mood effects of marijuana while 
decreases in rCBF in the temporal auditory and attention areas of the brain are thought to 
be associated with the perceptual effects of marijuana29. O’Leary et al reported an 
increase in rCBF in the cerebellum after acute marijuana intoxication. Since the 
 
 
9 
cerebellum plays a role in timing of actions and perceived time, it is believed that this 
change in brain metabolism can be related to marijuana altering one’s sense of time.   
There are mixed opinions on precisely which cognitive domains are affected by 
acute marijuana use and intoxication. The most commonly reported cognitive impairment 
appears to be in memory, particularly in the area of recall, but some studies have reported 
deficits in attention and executive function27-29,33. Recall has been shown to decrease 
when information is presented to an individual while intoxicated, but there is no deficit in 
recall of information presented pre or post-intoxication27,31,35. Retrieval cues can help 
recall the information learned under the influence, so it appears that ∆9-THC disrupts 
access and organization of memories, or the retrieval of memories and not necessarily 
encoding31.  
 In an evidence review looking at the acute and residual effects of marijuana on 
cognition, Crean et al found that attention and executive functions such as information 
processing, inhibition and impulse control, and working memory were impaired due to 
acute use, but subsided after the initial period of intoxication26. Ramaekers et al extended 
these findings, reporting that high-potency marijuana caused deficits in impulse control 
during acute marijuana use33. Similarly, Lundqvist et al reported deficits in attention with 
relation to selection of relevant stimuli and filtering out irrelevant stimuli as well as a 
deficits in memory29. On the other hand, Kelleher et al found no effect of acute marijuana 
use on information processing32. Hart et al  also did not find any deficits of accuracy on 
neurocognitive tests regarding executive function, but did find that acute ∆9-THC 
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intoxication increased the time taken to complete these tasks and that premature 
responses were increased34. This could indicate deficits in inhibitory control.  
 
Residual Effects of Marijuana Use on Cognitive Function  
 Residual effects of marijuana include any effects on cognition that persist after 
intoxication (over four hours post-intoxication) and remain while ∆9-THC is leaving the 
system39. These effects are caused by any active ∆9-THC metabolites that remain in the 
CNS post acute marijuana intoxication39. While ∆9-THC has a half-life of 2-60 hours, its 
effects can still persist well after acute intoxication due to the redistribution of ∆9-THC 
from the plasma into the tissues39. It accumulates in the fat of chronic users and can build 
up in the system. Thus, residual effects can range from 12-24 hours post intoxication to 
days or weeks later depending on how often an individual smokes marijuana39.  
There is still much debate concerning the residual effects of marijuana on 
cognition28. In a meta-analysis of the non-acute, cognitive effects of marijuana use, 
Schreiner et al found a negative impact of marijuana in the domains of executive 
function, attention, language, perceptual-motor, and learning and memory in individuals 
abstinent for less than 25 days40. In another meta-analysis looking at the residual effects 
of marijuana, Grant et al found that there were small but significant residual effects of 
marijuana on learning and forgetting with evidence of an increased recency effect when 
learning new material41. They also found a small negative global effect in chronic 
marijuana users, all of which were abstinent from marijuana for at least 24 hours41. Pope 
et al found evidence of impaired memory in heavy marijuana users for up to 7 days post-
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cessation in two consecutive studies, and Battisti et al furthered these findings showing 
that heavy marijuana users show deficits specifically in memory recall after 12 hours of 
cessation42-44. Battisti et al  also showed that chronic marijuana users show a decrease in 
accuracy of the Stroop task 12 hours post-cessation of marijuana, which could reveal 
deficits in executive function such as inhibition control45. Solowij et al reported that long-
term, heavy marijuana users showed deficits on memory and attention tasks in the areas 
of learning, retrieval, and retention48. These deficits were found to worsen with years of 
use and persist despite marijuana cessation for at least 12 hours prior to participating in 
the study48. Chronic marijuana users have also been shown to make more errors and need 
more time when completing neurocognitive assessments upon cessation of marijuana 
use48. It is thought that these compensation strategies could be masking an even worse 
cognitive dysfunction. Alternatively, Chang et al and Kanayama et al found no significant 
difference on any neuropsychological tests in chronic marijuana users who were abstinent 
from marijuana for at least 4 hours prior to administration of the tests47,52.  
 
Marijuana Withdrawal  
 In addition to the inconsistent findings regarding the residual effects of marijuana 
use, it is oftentimes unclear whether the residual effects mentioned previously are due to 
withdrawal symptoms or the actual effects of ∆9-THC metabolites remaining in the 
system since the period of marijuana abstinence in many studies is extremely variable, 
ranging from hours to weeks. The DSM-5 has defined a cluster of symptoms termed 
“cannabis withdrawal” which can include: irritability, anger, aggression, anxiety, sleep 
 
 
12 
disturbance, decreased appetite or weight loss, restlessness, depressed mood, stomach 
pain, tremors, sweating, fever, or headache. The onset of symptoms is found to appear 1-
2 days after abrupt cessation in 50% of marijuana users38. Some symptoms such as sleep 
disturbances and irritability appear to persist longer than others38. It is reasonable to 
suspect, then, that these documented withdrawal symptoms may be confounding the 
residual effects of marijuana on cognition.   
 
Long-Term, Persistent Effects of Marijuana Use on Cognitive Function  
Long-term, persistent effects of marijuana include any cognitive deficits that 
remain after all of the ∆9-THC and its metabolites have left the system39. As with residual 
effects of marijuana, there is still conflicting evidence as to whether lasting CNS effects 
exist and what domains of cognitive function may be affected. In a meta-analysis looking 
at the residual effects of marijuana, Schreiner et al found that while marijuana was shown 
to produce global, residual effects on cognition in individuals abstinent for less than 25 
days, all deficits subsided after one month of abstinence40. Simiarly, Pope at al. found 
that deficits in memory were present on days 0-7-post abstinence in heavy marijuana 
users, but all negative effects on cognition subsided by 28 days. Jager et al also found that 
there were no long-term deficits of marijuana in working memory or selective attention 
after one week of abstinence42,43,51. On the other hand, Gonzalez et al reported that the 
very small, negative effect that marijuana use has on memory is only present in heavy, 
long-term users upon cessation of marijuana use27. In support of the findings of Gonzalez 
et al, Bolla et al found that heavy marijuana use was associated with worse performance 
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on language, visual learning and memory, executive functions, psychomotor speed, and 
manual dexterity even after 28 days of abstinence49.  
 
Effects of Long-Term Marijuana Use on the Brain  
Despite mixed evidence of marijuana’s cognitive effects beyond those of acute 
use and intoxication, there is evidence that long-term, persistent marijuana use effects 
brain activity and metabolism even when all of the ∆9-THC has left the system. An 
altered brain activity pattern is probably the most common feature of marijuana’s 
influence on the brain. Lundqvist et al reported that marijuana users show 9% lower brain 
activity than non-users29. Kanayama et al also reported that marijuana users displayed 
more widespread brain activation during working memory task performance in which 
supplementary brain regions were recruited47. Chronic marijuana users have also been 
shown to have an altered brain activation pattern in attentional neural networks with a 
decrease in activation in normal attention areas, and an increase in smaller, compensatory 
regions33. All of these findings support the hypothesis that marijuana use induces a 
recruitment of alternate neural networks and neuroadaptation to compensate for subtle 
neural deficits caused by frequent marijuana use29. A decrease in rCBF in memory related 
areas of the prefrontal cortex, an increase in rCBF in cerebellar memory regions (with 
decreased activation upon cessation), and altered lateralization of activity in the 
hippocampus have also all been observed29,46. Upon intoxication however, experienced 
marijuana users show an increase in brain metabolism and a dose related increase in 
CBF29.  
 
 
14 
These findings are important because while cognitive deficits might subside upon 
abstinence from marijuana, there are still notable differences in brain metabolism and 
activation in heavy marijuana users using marijuana for long periods of time. This raises 
the question of whether comorbid conditions like HIV-infection may exacerbate these 
underlying brain disturbances and cause them to possibly reach a threshold where they 
will become manifested clinically.  
 
Marijuana and HIV  
 Despite any deficits in cognition that may be induced by marijuana use, marijuana 
is thought to have potential therapeutic benefits. Marijuana has been legalized for 
medicinal use in 23 states in the United States with four states having legalized 
recreational marijuana use93. Marijuana is thought to possess anti-nociceptive qualities by 
acting at the level of the thalamus in the brain26. Through injecting cannabinoids into the 
peri-aqueductal grey area of the brain, a region that sends afferent nerves reporting 
noxious stimuli from the spinal cord to the thalamus, researchers were able to diminish 
pain26. It is thought that ∆9-THC activates inhibitory neurons projecting from the brain 
stem to spinal cord to inhibit pain26. ∆9-THC has also been shown to enhance the anti-
pain effects of opioids26.  
Pain is one of the symptoms of HIV-infection that has the potential to be 
mitigated by medicinal marijuana use. In a study of pain frequency in women living with 
HIV and AIDS, it was found that 20% of individuals reported that they were often in 
pain, with peripheral neuropathy, tingling, numbness, musculoskeletal, and abdominal 
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pain being the most frequent types26,27. Other symptoms associated with HIV-infection 
can occur as a direct or indirect result of the disease or in reaction to HAART treatments. 
These can include: nausea/vomiting, reduced appetite, weight loss, headaches, anxiety, 
and depression27. 27% of HIV-infected individuals use marijuana to treat HIV-related 
symptoms, with pain and decreased appetite relieved the most by marijuana use27. 
Richardson et al has reported that frequency of pain is associated with a higher frequency 
of marijuana use89.  
In light of studies reporting deleterious effects of marijuana on cognitive function, 
and evidence that individuals are using marijuana as a therapeutic agent, it is important to 
know if there is a negative, additive effect of marijuana use and HIV-infection on 
cognitive function, especially if it will negatively impact an individual’s daily 
functioning, particularly their ability to abide by complicated medication regimes50. Fisk 
et al reported that marijuana use may create deficits in real-world memory function and 
other areas of executive function which correlated closely to daily functioning abilities50. 
 Despite this pressing question, few studies have looked at the interaction of HIV 
and marijuana on cognitive function. Chang et al reported that there was no negative 
interaction of marijuana use and HIV on cognitive function52. However, Cristiani et al 
found that marijuana use is associated with greater cognitive dysfunction in symptomatic 
HIV-infection, mostly in the domain of delayed memory, which is similar to what is seen 
in acute marijuana use90. The findings of Cristiani et al lend support to the idea that minor 
cognitive deficits caused by marijuana use that are not necessarily manifested clinically 
are exacerbated when combined with the comorbid condition of HIV-infection.  
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The Effects of Alcohol Use on the Brain and Cognition   
 It is widely accepted that alcohol causes cognitive dysfunction ranging from acute 
intoxication to an assortment of dementias. Ethanol, the compound contained in alcoholic 
beverages, is believed to affect the brain directly and indirectly. While there is still a 
debate as to what the molecular targets of ethanol might be in the brain, it is believed that 
ethanol interacts with proteins, such as enzymes and ion-channels, on neurons to cause its 
cognitive and behavioral effects56. In the neurotoxicity hypothesis, ethanol is thought to 
directly induce neuronal loss and dysfunction through glutamate excitotoxicity, oxidative 
stress, and disruption of neurogenesis53. Ethanol is thought to inhibit N-methyl-D-
aspartate (NMDA) receptors, which ultimately increases glutamate, and the excitotoxic 
response in neurons53,54. Ethanol has also been found to cause damage to DNA in 
neurons54.  
Indirect damage of ethanol to the CNS can be caused by malnutrition commonly 
accompanied by alcohol use disorders as well as metabolism disturbances caused by 
alcohol use. Alcoholics are known to consume less thiamine (Vitamin B1), with ethanol 
also compromising thiamine metabolism53. This lowers the concentration in the plasma, 
causing acute neurological disorders53. Also, increased ethanol consumption is associated 
with increased homocysteine residues in the brain, which are found to intensify 
excitotoxic damage55.  
Ethanol is also believed to induce a pro-inflammatory state in the brain that can 
contribute to the indirect damage of alcohol on cognitive dysfunction. Zhao et al found 
that intermittent ethanol exposure increased the number of activated microglia and pro-
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inflammatory cytokines in the hippocampus, parietal association cortex, and entorhinal 
cortex which was associated with cognitive deficits in memory58. He et al also found that 
there was an increase in monocyte chemoattractant protein 1 (MCP-1) in the ventral 
tegmental area, substantia nigra, hippocampus, and amygdala59. MCP-1 is thought to 
mediate CNS inflammation and possibly drinking behavior, and has been shown to be 
related to the neurodegeneration found in brains of alcoholics59. Dysfunction of the 
cingulate cortex has been shown to be related to attentional dysfunction59.  
 Overall, deleterious effects of alcohol are shown to be most prominent in the 
frontal lobe, with abnormalities in different regions of the frontal lobe being associated 
with different cognitive deficits54. Cortical atrophy, ventricular enlargement or increased 
CSF, meningeal thickening, cell loss, and architectural disruption of cortical laminae 
have all been reported in the frontal lobes54,55. Cortical atrophy has been shown to be 
proportional to the amount of alcohol consumed in a lifetime54,55. Changes in both white 
and gray matter have been observed, with white matter showing more striking negative 
effects due to myelin loss than loss of grey matter due to neurotoxicity76. However, loss 
of grey matter is most associated with cognitive deficits76. Dendritic and synaptic 
changes are believed to produce cognitive deficits that precede severe structural 
changes54. A decrease in glucose metabolism, NAA, choline (a marker of membrane 
integrity), and creatine (a measure of cell energy) have also been found in the frontal 
lobes of alcoholics54.  All frontal lobe abnormalities have been shown to improve after 
prolonged abstinence54,55. 
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Other areas of the brain that have been shown to have pathologies are the corpus 
callosum, cerebellum, hypothalamus, and hippocampus53. Despite observed effects of 
alcohol on memory, the hippocampus has not shown to be subject to neuronal loss, but to 
have dendrite and axonal damage82.  
 Alcohol can be thought to effect cognition on a continuum ranging from mild 
cognitive impairment to the more severe Wernike-Korsakoff’s syndrome (WKS) and 
alcohol related dementia (ARD)67. The main domains of cognition affected by alcohol 
appear to be memory, attention, psychomotor, and executive function, with alcoholics 
showing deficits and lower efficiency on neurocognitive tests67.  The cognitive effects of 
alcohol also depend on what type of exposure an individual has had. For instance, acute 
effects of alcohol could be due to social or binge-drinking, while chronic effects on 
cognition may arise due to prolonged, heavy use. Withdrawal from alcohol has also been 
known to cause and worsen cognitive deficits.  
 
Effects of Acute Alcohol Use on Cognition  
 Acute exposure to alcohol includes the time-period when alcohol is in an 
individual’s system. The acute effects of alcohol on cognition are thought to vary 
depending on if an individual is drinking at “moderate levels”, or at hazardous levels seen 
in episodes of binge-drinking. Binge-drinking is defined as consuming hazardous 
amounts of alcohol in a limited period of time followed by a period of abstinence. 
Typically, ≥ 5 drinks for men and ≥ 4 drinks for women in a span of 24 hours is 
considered hazardous62. According to the DSM-5, alcohol intoxication is accompanied by 
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slurred speech, incoordination, unsteady gait, nystagmus, impaired attention and memory, 
and stupor or coma. Weissenborn et al found that in general, acute alcohol use impairs 
executive functions such as planning and spatial recognition with binge-drinking 
effecting spatial working memory60. Townshend et al furthered these findings, reporting 
that binge-drinking impairs not only spatial working memory but motor impulsivity, 
sustained attention, and impulse control61. Both findings from Weissenborn et al and 
Townshend et al reveal deficits in executive function, which is known to be represented 
in the frontal lobes.  
 It seems that the predictor of cognitive dysfunction due to moderate, acute use of 
alcohol and binge-drinking is not necessarily the amount of alcohol an individual drank 
in a given time, but the magnitude of the effect that that amount of alcohol had on each 
person specifically since variables like age and gender can influence one’s sensitivity to 
the effects of alcohol61,108. Therefore, the acute effects of alcohol on cognition can be 
extremely variable, and it is difficult to generalize the type of consequences drinking may 
have on cognition62,108.  
 Related to binge-drinking is alcohol withdrawal, since binge-drinking by 
definition includes a period of alcohol abstinence. According to the DSM-5, withdrawal 
can occur several hours to a few days post alcohol cessation. Symptoms include 
autonomic hyperactivity, increased hand tremor, insomnia, nausea, hallucinations, 
psychomotor agitation, anxiety, tonic-clonic seizures as well as cognitive impairments21. 
Repeated alcohol withdrawal has been shown to increase the risk of withdrawal 
associated seizures and cognitive deficits62,66. In a study by Duka et al looking at the 
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effects of previous ethanol withdrawal on cognition, they found that impulsivity, 
specifically the inhibition of motor responses, was negatively affected66. This again, is an 
executive function controlled by the frontal lobe.  
 
Effects of Chronic Alcohol Use on Cognition  
 Excessive, prolonged alcohol use, as occurs with alcoholism and alcohol 
dependence also causes cognitive deficits associated with frontal lobe damage 
exemplified in WKS and ARD. ARD is defined as persistent cognitive and functional 
decline following cessation of alcohol as a direct result of the neurotoxic effects of 
alcohol on the brain53. ARD accounts for 1.4% of all dementia patients, but 22% of all 
dementia patients under the age of 6553. Neurocognitive deficits associated with ARD 
appear to be both cortical and subcortical, with visuospatial, working memory, motor 
speed, and executive function being the most prominent areas with deficits53. WKS is 
defined as an alcohol induced persisting amnestic disorder with characteristic memory 
disturbances and is the result of thiamine deficiency and most likely some degree of 
neurotoxicity due to ethanol53. Wernicke’s encephalopathy is the direct result of 
decreased thiamine, which is followed by a triad of oculomotor, cerebellar, and mental 
state abnormalities53. This is then followed by memory impairment termed Korsakoff’s 
Syndrome53. WKS syndrome is prevalent in about 1-2% of the general population and 
10% of those with alcohol use disorders53. Neurocognitive deficits associated with WKS 
are mostly manifested as memory impairments, represented by anterograde amnesia and 
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impaired recall53. Impaired visuoperception, executive function, and working memory 
have also been reported53.  
 The period of time and amount of alcohol required for ARD and WKS to manifest 
is inconsistent in the literature due to there being many different definitions for standard 
drinks and what is considered heavy drinking across different cultures101. Generally, in 
the United States, a “standard drink” is considered 14 grams of pure alcohol or 12 ounces 
of regular strength beer, 5 ounces of wine, and 1.5 ounces of hard liquor. There have been 
reports that consuming 70-80 grams (the equivalent of 5-6 standard drinks) of alcohol per 
day will cause mild cognitive dysfunction101. It is also been reported that after five years 
of consuming 35 standard drinks a week for men and 28 standard drinks a week for 
women, the risk of ARD is significant due to an increased neurotoxicity101. In general, it 
is believed that there is a U-shaped relationship between alcohol use and dementia, with 
low to moderate levels possibly causing a decrease in risk for cognitive dysfunction and 
heavy drinking causing an increased risk101.  
The Effects of Alcohol Use on Cognition May be Reversible  
In general, the cognitive deficits found in sober individuals with previous alcohol 
use disorders (that do not have ARD or WKS) have been shown to be mitigated, if not 
reversed, by abstinence. Abstinence of one week or more can resolve much of the 
cognitive dysfunction in individuals with alcohol related disorders53,65,67. In a study of 
abstinent alcoholic men and women, Fein et al only found mild deficits in spatial 
processing in long-term, abstinent alcoholic individuals65.  Deficits in executive function, 
working memory, and perceptual and motor impairments appear to last longer than verbal 
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and visual-spatial impairments53. Female sex, increased age, and decreased education 
level all appear to be related to worse cognitive outcomes and worse recovery of 
cognitive dysfunction in chronic alcoholics53,66. Recovery also appears to be related to the 
amount of recent alcohol use and duration of abstinence rather than lifetime use53,66. 
Multiple withdrawals also appear to be associated with worse cognitive outcomes53.  
 
Alcohol and HIV 
 As stated previously, alcohol use among HIV-infected individuals is particularly 
high. An increased prevalence of alcohol use among HIV-infected people is dangerous 
for a number of reasons. Alcohol increases sexual risk behavior, with 33% of individuals 
having consumed alcohol before engaging in sexual activities68. Thus, it is likely that 
alcohol may contribute to the spread of HIV. Also, hazardous drinking decreases an 
individual’s adherence to HAART regimens71,73,77. Since any adherence less than 95% 
decreases the benefit of HAART, it is essential that it is maintained71. In a study 
examining the effects of alcohol consumption on life expectancy in HIV-infected 
individuals, Braithwaite et al showed that a 33% decrease in treatment success decreased 
an individual’s life expectancy by 3.3 years71.  
 Not only does alcohol possibly facilitate worse disease outcomes in those with 
HIV-infection, there is evidence to show that alcohol and HIV act synergistically in the 
CNS to produce negative effects on cognition and brain pathology. Alcohol has been 
shown to mainly affect the frontal lobes while HIV mainly affects central white matter 
and subcortical structures like the basal ganglia with there being little overlap in the 
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structures involved in the pathology of either condition separately. However, affects on 
central white matter, subcortical gray matter, and the frontal cortex have been shown to 
be exacerbated due to the comorbid conditions82. Pfefferbaum et al, in two separate 
studies looking at the additive effects of alcohol and HIV on the ventricles, corpus 
collosum, and white matter, showed that the comorbid conditions combine to effect the 
structural integrity of the brain as seen in neuroimaging techniques such as Magnetic 
Resonance Spectroscopy (MRS), Magnetic Resonance Imaging (MRI), and Diffusion 
Tensor Imaging (DTI)83,84. These effects cannot be described in those with HIV-infection 
or alcoholism separately83,84. These deficits were mainly reflected in altered mirco and 
macro structural integrity of the corpus collossum83,84. There have also been documented 
synergistic effects on cell membrane metabolism in the brain as can be seen in a decrease 
in phosphodiesterase (PDE), phosphocreatine (PCr), and adenosine triphosphate 
(ATP)83,84.  
There are many different cognitive domains that are thought to be affected by the 
additive effects of alcohol and HIV-infection, some of which include: motor, visuomotor, 
verbal reasoning, reaction time, auditory processing, associative learning, attention, 
memory, and executive function13,20,22,72,74,75,76,78-82. Memory has specifically been shown 
to be influenced in the areas of free recall and sequencing78. These cognitive impairments 
are thought to be the product of a threshold effect. The impairments of alcohol and HIV-
infection on cognition separately may not be detected, but over time the comorbid 
conditions act synergistically, crossing a threshold of brain damage that manifests 
clinically as cognitive dysfunction78. In a study on attentional control in HIV-infected 
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individuals who also had alcohol use disorders, Schulte et al found that separately, HIV-
infected individuals without alcohol use disorders and individuals without HIV-infection 
with alcohol use disorders performed the same as controls on neurocognitive tests of 
attention80. However, the deficits became apparent in alcoholics with HIV-infection80.  
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SPECIFIC AIMS 
 
 The present study looks at the association of current and lifetime marijuana and 
heavy alcohol use on cognitive function in HIV-infected individuals.  There is quite a bit 
of evidence showing that HIV-infection, marijuana use, and alcohol use all affect 
cognition individually. Similarly, there is some support that HIV-infection in 
combination with marijuana use, as well as HIV-infection in combination with alcohol 
use also affects cognition in a negative, additive manner. However, there is a lack of data 
considering the effects of the combination of alcohol, marijuana, and HIV-infection on 
cognitive function. It is reasonable to hypothesize that individuals who use marijuana, 
drink heavily and have HIV-infection may be subject to additive, negative or even 
synergistic effects of all three conditions on the brain, cognition, and ultimately daily 
functioning.  Our main objectives were as follows:  
 
Among individuals with current substance dependence or ever injection drug use and 
HIV-infection:  
1.) To test if current marijuana use is associated with cognitive dysfunction;  
2.) To test if current heavy alcohol use is associated with cognitive dysfunction;  
3.) To test if lifetime marijuana use is associated with cognitive dysfunction;   
4.) To test if lifetime, heavy alcohol use is associated with cognitive dysfunction;  
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5.) To test if lifetime marijuana use and lifetime heavy alcohol use are 
synergistically associated with cognitive dysfunction; 
6.) To test if current marijuana use and current heavy alcohol use are 
synergistically associated with cognitive dysfunction. 
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METHODS 
Design and Human Subjects Approval  
Using cross-sectional, regression analyses, we attempted to determine whether or 
not there are associations between current and lifetime marijuana use, heavy alcohol use, 
and cognitive dysfunction in HIV- infected individuals. The Institutional Review Board 
(IRB) of Boston Medical Center reviewed and approved all study procedures.  
 
Sample 
Participants were a part of the Boston ARCH cohort which is comprised of 250 
HIV-infected individuals affected by multiple substances and is one of three cohorts that 
make up the URBAN ARCH (Uganda Russia Boston Alcohol Network for Alcohol 
Research Collaboration on HIV/AIDS) consortium. Recruitment and data collection took 
place between September of 2012 and November of 2014. For this analysis, participants 
were required to have completed the lifetime drug and alcohol data assessments, taking 
place 6 months or more after the baseline assessment. This resulted in a loss of 35 
individuals for a final sample of 215.  Participants were recruited from clinical sites of 
HIV care in Boston, Massachusetts including the Center for Infectious Disease at Boston 
Medical Center and the Boston Healthcare for the Homeless program.    
 Inclusion criteria for Boston ARCH included documentation of HIV-infection in 
participants’ medical records which could consist of: an ELISA testing for HIV 
antibodies confirmed by Western blot, having a viral load of > 10,000, a 4th generation 
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ELISA (Enzyme Linked Immunosorbent Assay) confirmed by “Multi-Spot” rapid test, or 
nucleic acid testing for HIV-1. Participants were required to have current drug or alcohol 
dependence in the 12 months prior to entering the cohort or current or past injection drug 
use. They were required to speak fluent English, be 18 years or older, and be able to 
provide contact information for one person who knew of their whereabouts to assist in 
locating them for follow up interviews. Exclusion criteria were pregnancy, plans to leave 
the Boston area within the year, and cognitive impairment that could inhibit an individual 
from being able to give informed consent or understanding interview questions as 
assessed by trained research staff.  
 
Data Collection  
Data were collected by research assistants by interview and collection of urine 
and blood samples. An initial baseline screening interview was administered to each 
participant after obtaining oral consent to view their medical records to confirm HIV-
infection. The baseline screener included all inclusion and exclusion criteria. Next, a 
baseline assessment questionnaire was administered by in person interview. All data used 
for analyses herein were obtained by the screening interview, the baseline assessment, 
and electronic medical record review except for the lifetime alcohol and marijuana use 
data which were obtained at a six month or one year follow up contact.  
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Independent Variables  
There were five independent variables also depicted in Figure 1 below: current 
marijuana use, current heavy alcohol use, lifetime marijuana use, and two measure of 
lifetime heavy alcohol use. Current use variables were defined as number of days of 
marijuana use in the past 30 days for marijuana and number of heavy drinking days in the 
past 30 days for alcohol. Current marijuana use was measured using questions adapted 
from the validated, 30-Day Drug Addiction Severity Index (ASI) (See Appendix A) 99,100. 
The Interviewer read, “Now I am going to ask you some questions about your drug use in 
the past 30 days. How many days in the past 30 days have you used…” and participants 
were to report how many days they had used a number of different drugs, including 
marijuana. Current heavy alcohol use was measured using the 30-day Timeline Follow-
Back method (TLFB) (See Appendix B). This is a self-report calendar measure that looks 
at an individual’s drinking patterns and behavior on each of the past 30 days and has been 
validated for use in people with HIV-infection85. Research assistants asked participants 
about their use of alcohol on each day for the 30 days prior to the interview. If alcohol 
was used, subjects reported the type and quantity of standard drinks for each day, with 
“standard drinks” meaning 12 ounces of regular strength beer, 5 ounces of non-fortified 
wine, and 1.5 ounces of 80 proof liquor. These quantities were then converted to the gram 
equivalent of 14 grams of pure alcohol. A heavy drinking day was defined as ≥ 5 drinks 
in 24 hours for males and ≥ 4 drinks in 24 hours for females.  
Lifetime variables were defined as follows: number of years marijuana was used 
≥ 3 times per week, lifetime alcohol consumption in kilograms (kg), and duration of 
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heavy drinking in years. Lifetime marijuana use was measured at the six-month 
assessment and at any following appointments if the six-month assessment was missed 
using selected questions from the ASI (See Appendix C). The portion of the ASI included 
in the follow up appointments was adapted from the 30 day Drug ASI to measure how 
many years participants regularly used a variety of drugs ≥3 times per week, including 
marijuana. Participants were asked, “How many years in your life have you regularly 
used…” and were to report this number for each drug. Lifetime alcohol consumption in 
Kg was measured starting at the six-month assessment and at any follow up appointments 
if the six-month assessment was missed using the validated lifetime drinking history 
(LDH) self-report questionnaire (See Appendix D)102,103. Participants were asked to recall 
their drinking patterns throughout life starting at the point when they began to drink 
regularly up until the day of the interview. Specifically, they were asked when they began 
to drink regularly, if there were any events that led their drinking behavior to change, and 
the frequency of drinking during any periods of regular drinking. Periods of regular 
drinking were considered to be any time participants had at least one standard drink a 
month, with “standard drink” still defined as 12 ounces of regular strength beer, 5 ounces 
of non-fortified wine, and 1.5 ounces of 80 proof liquor. These data were then converted 
to total lifetime alcohol exposure in kilograms (Kg). Duration of heavy drinking was 
taken from the same assessment, but was defined as the number of years a participant 
drank > 84 grams of alcohol or > 6 drinks per day throughout their life.  
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Dependent Variables 
All three dependent or outcome variables measured cognitive dysfunction as 
depicted in Figure 1 below and included: the Montreal Cognitive Assessment (MoCA) 
memory score, MoCA attention score, and Medical Outcomes Study HIV Health Survey 
(MOS-HIV) CF4 sore. The MoCA is a rapid screening measure for cognitive dysfunction 
that takes approximately 10 minutes to administer. It assesses various aspects of 
cognition including attention and concentration, executive function, memory, language, 
visuocontructional skills, conceptual thinking, calculations, and orientation. It has been 
validated for use in HIV-infected people and its different domains have also been shown 
to be positively correlated with other neuropsychological tests in similar areas of 
cognition86,87. In this study, we used the memory and attention domains of the MoCA 
(See Appendix E). The memory portion tested participants’ recall. The interviewer read 
each participant a list of words that they had to recall directly after the first two trials and 
again five minutes later. Participants could recall a maximum of five words in each trial. 
For each word recalled correctly, they received a “1” and for each word not recalled they 
received a “0,” yielding a minimum of 0 and a maximum of 5 points per trial. The 
attention portion tested individuals on their ability to repeat a sequence of numbers 
exactly as the interviewer read them in the first trial and then to repeat a different set of 
numbers backwards in the second trial.  Participants either received a “1” for repeating 
each sequence correctly or a “0” for repeating them incorrectly, resulting in a minimum 
of 0 and maximum of 2 points for both trials combined.  
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The MOS-HIV is a brief, validated measure looking at the health-related quality 
of life of those with HIV-infection89. It is comprised of 35 questions that make up 11 
separate domains including: general health perceptions, pain, physical functioning, role 
functioning, social functioning, energy/fatigue, mental health, health distress, cognitive 
functioning, quality of life, and health transition. The raw scores are linearly transformed 
to a 1-100 point scale with higher scores indicating better health. In the present study, 
only the domain of cognitive function was used (CF4). This section is composed of four 
questions related to cognitive function (See Appendix F).   
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Independent Variables 
Current and Lifetime marijuana and 
heavy alcohol use measures 
Dependent Variables 
Measures of Cognitive Dysfunction 
Current Marijuana Use 
# of days of marijuana use in the 
past 30 days  
 
MoCA Memory Score 
Memory section of the MoCA testing 
recall of five words directly after hearing 
them and five minutes later.  
Two trials were ran using the same five 
words, after the second participants were 
asked to recall those five words five minutes 
later 
Participants received 0 for each word not 
recalled and 1 for each word recalled with a 
range of 0-5 possible points for each trial  
Current Alcohol Use 
# of heavy drinking days in the 
past 30 days  
 
MoCA Attention Score 
Attention section of the MoCA consisting 
of two trials requiring participants to repeat a 
sequence of 5 numbers exactly as the 
interviewer said them in the first, and then 
repeat a sequence of 3 numbers in reverse in 
the second 
 Participants received 0 if the sequences 
were repeated incorrectly and 1 if repeated 
correctly for a range of 0-2 points between 
both trials  
Lifetime Marijuana Use 
# years marijuana was used ≥ 3 
times per week  
 
MOS-HIV CF4 Score 
4 Questions regarding cognitive function 
taken from the MOS-HIV 
 Scores were converted to a 0-100 point 
scale with a higher score indicated better 
health.  
Lifetime Alcohol Use 
Lifetime Alcohol Consumption 
(Kg) 
 
 
Lifetime Alcohol Use 
Duration of Heavy Drinking 
  # of yrs. participants drank > 6 
drinks or >84 grams/day 
 
 
 
Figure 1.  Independent and Dependent Variables used in Analyses  
Left column: Independent variables used for current and lifetime marijuana and heavy alcohol 
use and how each variable was measured listed in italics.  
Right column: Dependent variables used for cognitive dysfunction and how each were measured 
listed in italics.  
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Analysis 
Descriptive statistics were calculated for the independent variables, dependent 
variables and all covariates as shown at the beginning of the results section in Table 1. 
This included the median, mean, standard deviation, range, upper, and lower percentiles 
for any continuous variables and frequencies and proportions for any dichotomous 
variables.  
Analyses consisted of unadjusted, core-adjusted, and fully adjusted models. 
Covariates adjusted for included a group of “core” covariates to definitively be included 
in the analyses and those determined after considering a Spearman correlation matrix and 
bivariate analyses, creating a full list of covariates. The Spearman correlation matrix was 
generated for all covariates and independent variables to check for co-linearity. If any 
variables were correlated > 0.40, only one of them was included in the regression models. 
Bivariate analyses were used to assess any associations between all covariates or 
independent variables and all cognitive outcomes. (see Table 2 in results section). Core 
covariates included: age, biological sex, race, education level, primary language, 
employment status, and depressive symptoms taken from the patient health questionnaire 
(PHQ-2). The full group of covariates chosen included the core plus: the Charlson 
Comorbidity Index Score obtained from participants’ medical records, anxiety symptoms 
from the overall anxiety severity and impairment scale (OASIS), hepatitis C infection 
(ever) determined by a positive antibody test or a viral load of > 0, whether or not 
participants were currently on HAART, HIV viral load, current CD4 cell count, duration 
of HIV-infection, lifetime cocaine use (years of regular use equivalent to 2 binges per 
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week) taken from the adapted lifetime ASI, past 30 day cocaine use from the 30-Day 
Drug ASI, past 30 day sedative or opioid use from the 30-Day Drug ASI, and whether or 
not participants had a current prescription for opioids. The Charlson Comorbidity Index 
is a validated way to predict the risk of mortality in one year based on 19 predetermined 
comorbidities that have been assigned weights of 1,2,3, and 694,95. These are then added 
together for a total score which takes into account the number and seriousness of 
comorbid conditions, with higher scores indicating a higher risk for mortality94,95. The 
PHQ-2 is a validated, two-item questionnaire which assesses depression severity96. A 
score of ≥ 3 indicates symptoms of depression96. The OASIS is a validated, five-item 
questionnaire used primarily to identify anxiety disorders, but also to assess the 
frequency and intensity of anxiety symptoms and any functional impairment related to 
these symptoms97,98. A score of ≥8 indicates symptoms related to an anxiety disorder97,98.  
Multivariable logistic and linear regression models were then fit to test the 
associations between all five independent variables and all three dependent variables. All 
independent variables were modeled as continuous as they represented a range of 
marijuana use and heavy alcohol consumption for both current and lifetime use. The 
MoCA memory score and MOS-HIV CF4 score were also modeled as continuous 
variables since participants were able to score between 0-5 and 0-100 on each test 
respectively. The MoCA attention score was dichotomized between individuals who 
scored either a 0 or a 1 or those who scored a 2. Linear regression was used in all models 
testing an association between the independent variables and both the MoCA memory 
and MOS-HIV CF4 outcomes while logistic regression was used when testing an 
 
 
36 
association between the independent variables and the MoCA attention outcome. 
Adjusted and unadjusted models were fit using the covariates listed previously. All 
models were first core-adjusted, and then fully adjusted using only the core covariates 
and then all covariates respectively.  
There were 8 different groups of multivariable regression models fit, 6 of which 
are described in Figure 2 below. In Group 1, we tested associations between current 
marijuana use and each cognitive outcome. In Group 2, we tested associations between 
current heavy alcohol use and each cognitive outcome. In Group 3 we tested associations 
between lifetime marijuana use and each cognitive outcome. In Group 4, we tested 
associations between lifetime alcohol use (kg) and each cognitive outcome. In Group 5, 
lifetime marijuana use, duration of heavy drinking, current heavy alcohol use, and current 
marijuana use were tested for associations with each cognitive outcome. In Group 6, 
lifetime marijuana use, lifetime alcohol use (kg), current heavy alcohol use, and current 
marijuana use were tested for associations with each outcome. In Group 7, the interaction 
between current heavy alcohol and current marijuana use was tested for each cognitive 
outcome. In Group 8, the interaction between lifetime marijuana and total lifetime 
alcohol use was tested for each cognitive outcome. All groups were fit using unadjusted, 
core-adjusted, and fully-adjusted models as stated previously.   
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 Independent Variables  
Group 
Number of 
Multivariable 
Regression 
Models  
Current 
Marijuana Use 
Current Heavy 
Alcohol Use 
Lifetime 
Marijuana Use 
Lifetime 
Alcohol Use 
(Kg) 
Duration of 
Heavy alcohol 
Use 
1 +     
2  +    
3   +   
4    +  
5 + + +  + 
6 + + + +  
 
Figure 2.  Multivariable Linear and Logistic Regression Models  
Figure 2 depicts 6 of the multivariable regression models fit to assess associations between the 
five continuous independent variables and dependent variables. The MoCA Memory score and 
MOS-HIV CF4 score were continuous while the MoCA Attention score was dichotomous. Not 
shown in the table are Groups 7 and 8 which tested the possible interactions of current and 
lifetime marijuana and heavy alcohol use with each cognitive outcome respectively. Multivariable 
linear regression analyses were used when assessing associations between the independent 
variables and MoCA memory score and MOS-HIV CF4 score. Multivariable logistic regression 
analyses were used when assessing associations between the independent variables and the 
MoCA attention score. All analyses used unadjusted, core-adjusted, and fully-adjusted models.  
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RESULTS  
Descriptive Statistics  
Demographics 
 The mean age of participants was 49 years, 65% were male, and 20% were white. 
66% of participants completed high school or a high school equivalent, 17% were 
employed, and 86% reported English as their primary language. The mean Charlson 
comorbidity score was 2.9 with 59% having tested positive for HCV ever in their 
lifetime. Participants scored ≥ 3 on the Patient Health Questionnaire 2 (PHQ-2) 28% of 
the time indicating substantial depressive symptoms and 45% scored ≥ 8 on the Overall 
Anxiety Severity and Impairment Scale (OASIS) indicating potential anxiety disorders. 
Participants currently on HAART were 87%, 71% had an HIV viral load of < 200 
copies/mL, CD4 cell count/mm3 was 10%: <200 and 33%: 200-<500, and the mean 
duration of HIV-infection of 16 years. The mean years of cocaine use was 9.3, with 31% 
of people reporting that they had used the drug in the past 30 days. Illicit opioid use in the 
past 30 days was 26%, with 39% of participants reporting a current opioid prescription. 
Demographic statistics for all variables are reported in Table 1 below.  
 
. 
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Table 1. Descriptive Statistics for Independent Variables, Dependent Variables, and Covariates 
Descriptive statistics calculated for continuous variables included the mean, median, range, standard deviation (SD), upper 
quartile (UQ), and lower quartile (LQ). Descriptive statistics calculated for dichotomous variables were frequencies and 
percentages. Categories that dichotomous variables were dichotomized as are listed in italics underneath the variable name. 
Frequencies and percentages correspond to the fist, second, and third category respectively. ovariates 
 
 
 
 
 Continuous Variables 
Current 
Marijua
na Use 
(Days) 
Current 
Alcohol 
Use 
(Days) 
Lifetime 
Marijuana 
Use 
(Years) 
Lifetime 
Alcohol 
Use (Kg) 
Duration of 
Heavy 
Alcohol 
Use 
(Years) 
Charlson 
Comorbidity 
Index Score 
Age 
(Yrs) 
HIV 
Duration 
(years) 
HIV 
Viral 
Load 
(copies/
mL) 
Lifetime 
Cocaine 
Use 
(Years) 
MoCA 
Memory 
Score (1-
5) 
MOS-
HIV 
CF4 
Score 
(1-100) 
N 215 215 214 215 215 215 215 213 215 215 215 215 
Mean 6.5 4.8 9.8 720.7 6.4 2.9 48.6 16 1.56 9.3 3.2 68.8 
Median 0 1 5 326 1.1 2 50 16 1 7 3 70.8 
Range 30 30 48 6529.8 51.9 13 45 32.8 6.23 47 5 83.4 
UQ 7 6 16 812.2 11.1 4 56 23 2.7 15 4 83.3 
LQ 0 0 0 78 0 1 43 9 0 1 2 58.3 
SD 10.5 8.1 11.8 1079.8 9.5 2.5 9.5 8.4 1.7 9.8 1.3 18.9 
3
9
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Table 1 cont. Descriptive Statistics for Independent Variables, Dependent Variables, and Covariates 
Descriptive statistics calculated for continuous variables included the mean, median, range, standard deviation (SD), upper 
quartile (UQ), and lower quartile (LQ). Descriptive statistics calculated for dichotomous variables were frequencies and 
percentages. Categories that dichotomous variables were dichotomized as are listed in italics underneath the variable name. 
Frequencies and percentages correspond to the fist, second, and third category respectively. 
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 N 215 215 215 215 215 215 214 215 214 215 215 215 215 215 
Freq.  73, 142 43, 172 143, 72 184, 31 37, 178 140, 75 154, 60 119, 96 126, 88 187, 
28 
22, 71, 
122 
55, 160 66, 149 84, 131 
% 34, 66 20, 80 66.5, 
33.5 
86, 14 17, 83 65, 35 72, 28 55, 45 59, 41 87, 13 10, 33, 
57 
26, 74 31, 69 39, 61 
4
0
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Table 2. Bivariate Analysis  
Table 2 describes the results of the bivariate analysis used to assess any associations 
between covariates or independent variables and each outcome in order to determine a 
full list of covariates. OR means odds ratio from logistic regression analyses and CI 
means confidence interval.  
 
Independent  
Variable 
MoCA  
Attention  
Score n 
MoCA 
Attention 
Score  
OR 
(95%CI) 
MoCA 
Attention 
Score  
P-Value 
MoCA 
Memory 
Score n 
MoCA 
Memory 
Score β 
(95% 
CI) 
MoCA  
Memory 
P-Value 
MOS-
HIV 
CF4  
Score 
n 
MOS-
HIV 
CF4 β 
(95% 
CI)  
MOS-
HIV 
CF4  
P-
Value 
Lifetime 
Drinking 
(Kg) 
215 1.0 
(1.0, 1.0) 
0.7 215 0 
(-0.0001, 
0.0002) 
0.6 215 -
0.0004 
(-
0.003, 
0.002) 
0.8 
Duration of 
Heavy 
Drinking 
215 1.01 
(1.0, 
1.04) 
0.7 215 0.004 
(-0.01, 
0.02) 
0.6 215 -0.03 
(-0.3, 
0.2) 
0.8 
Lifetime 
Marijuana 
214 1.02 
(1.0, 
1.04) 
0.2 214 0.01 
(-0.003, 
0.03) 
0.1 214 0.01 
(-0.2, 
0.2) 
0.9 
Current 
Alcohol 
215 1.01 (1.0, 
1.04) 
0.8 215 -0.01 
(-0.03, 
0.01) 
0.3 215 0.06 
(-0.2, 
0.4) 
0.7 
Current 
Marijuana 
215 1.01 
(0.98, 
1.04) 
0.4 215 0.007 
(-0.097, 
0.02) 
0.4 215 -0.2 
(-0.3, 
0.4) 
0.3 
Age 215 1.0 
(0.9, 
1.00) 
0.05 215 -0.03 
(-0.05, -
0.01) 
0.0003 215 0.08 
(-0.2, 
0.3) 
0.6 
Sex 215 0.8 
(0.4, 1.4)  
0.5 215 0.006 
(-0.4, 
0.4) 
1.0 215 1.1 
(-4.2, 
6.4) 
0.7 
Race 215 1.4 
(0.7, 3.0) 
0.3 215 0.3 
(-0.1, 
0.8) 
0.2 215 -2.9 
(-9.2, 
3.5) 
0.4 
Education 215 0.4 
(0.2, 0.8) 
0.004 215 -0.5 
(-0.9, -
0.1) 
0.007 215 -6.7 
(-12, 
1.4) 
0.01 
Primary 
Language 
215 3.8 
(1.7, 8.4) 
0.009 215 0.5 
(-0.02, 
0.99) 
0.06 215 5.8 
(-1.4, 
13) 
0.1 
Employment 
Status 
215 0.4 
(0.2, 0.8) 
0.01 215 -0.2 
(-0.7, 
0.2) 
0.3 215 1.5 
(-5.2, 
8.3) 
0.6 
Charlson  
Comorbidity 
Index 
215 0.9 
(0.8, 1.0) 
0.08 215 -0.04 
(0.1, 
0.02) 
0.2 215 -0.3 
(-1.4, 
0.7) 
0.5 
PHQ-2 
Score 
214 1.6 
(0.8, 3.1)  
0.1 214 -0.3 
(-0.7, 
0.07) 
0.4 214 -17.2 
(-22.4, 
-12) 
<0.001 
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Table 2 cont. Bivariate Analysis  
Table 2 describes the results of the bivariate analysis used to assess any associations 
between covariates or independent variables and each outcome in order to determine a 
full list of covariates. OR means odds ratio from logistic regression analyses and CI 
means confidence interval.  
 
 
OASIS 
Score 
215 1.0 
(0.5, 1.7) 
0.9 215 -0.1 
(-0.5, 
0.2) 
0.7 215 -14.8 
(-19.2, 
-9.7) 
<0.001 
HCV (ever) 214 1.0 
(0.6, 1.8) 
1.0 214 -0.05 
(-0.4, 
0.3) 
0.2 214 2.5 
(-2.7, 
7.7) 
0.3 
Currently 
on HAART 
215 0.4 
(0.1, 1.0) 
0.06 215 -0.3 
(-0.8, 
0.2) 
0.05 215 7.4 
(-0.1, 
14.9) 
0.05 
HIV viral 
load 
215 1.1 
(0.9, 1.3) 
0.2 215 0.1 
(0.003, 
0.2) 
0.8 215 -1.4 
(-2.9, 
0.03) 
0.05 
CD4 count 215 0.6 
(0.2, 1.7) 
0.5 215 0.2 
(-0.4, 
0.9) 
0.008 215 0.3 
(-8.8, 
9.5) 
0.9 
HIV 
Duration 
213 1.0 
(0.9, 1.0) 
0.05 213 -0.03 
(-0.05, 
0.007) 
0.2 213 0.2 
(-0.1, 
0.5) 
0.2 
Lifetime 
Cocaine 
215 1.0 
(1.0, 
1.04) 
0.7 215 -0.01 
(-0.03, 
0.006) 
0.5 215 -0.1 
(-0.4, 
0.1) 
0.3 
Cocaine 
Past 30 
Days 
215 1.7 
(0.9, 3.3) 
0.09 215 -0.1, 
(0.5, 
0.2) 
0.09 215 -6.7 
(-12.2, 
-1.3) 
0.01 
Opioids 
Past 
30 Days 
215 1.9 
(1.0, 3.9) 
0.06 215 0.3 
(-0.05, 
0.7) 
0.5 215 -2.4 
(-8.3, 
3.4) 
0.4 
Prescribed 
Opioids 
215 1.5 
(0.8, 2.7) 
0.2 215 0.1 
(-0.2, 
0.5) 
0.1 215 0.8 
(-4.4, 
6.0) 
0.7 
 
 
Main Independent Variables  
The distributions for current marijuana and heavy alcohol use are shown in Figure 
3 below, and descriptive statistics can be found in Table 1. Participants reported a mean 
of 6.5 days of marijuana use in the past 30 days with a standard deviation of 10.5. The 
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mean number of heavy drinking days in the past 30 days was 4.8 with a standard 
deviation of 8.1.  
The distributions for lifetime marijuana and heavy alcohol use are shown in 
Figure 4 below and descriptive statistics can be found in Table 1. Participants used 
marijuana ≥3 times per week for a mean of 9.8 years with a standard deviation of 11. The 
mean duration of heavy alcohol use was 51.9 years with a standard deviation of 9.5 and 
the mean lifetime alcohol consumption of 720.7 Kg with a standard deviation of 1,079. 
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Figure 3. Distributions for Current Marijuana and Heavy Alcohol Use 
Top Graph: X-axis measures number of days marijuana was used in the past 30 days or 
current marijuana use and Y-axis measures the percentage of the sample. Bottom Graph: 
X-axis measures number of heavy drinking days in the past 30 days or current heavy 
alcohol use and the Y-axis measures the percentage of the sample.  
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Figure 4.  Distributions for Lifetime Marijuana and Heavy Alcohol Use 
Top graph: X-axis measures how many years marijuana was used ≥ 3 times per week or 
lifetime marijuana use and the Y-axis measures the percentage of the sample. Middle 
graph: X-axis measures the number of years participants drank >5 drinks/ 84 grams of 
alcohol per day or duration of heavy alcohol use and the Y-axis measures the percentage 
of the sample. Bottom graph: X-axis measures the total lifetime exposure to alcohol in 
kilograms or lifetime alcohol and the Y-axis measures the percentage of the sample.  
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Dependent Variables  
Distributions and frequencies for cognitive dysfunction outcomes are listed in 
Figure 5 below and descriptive statistics can be found in Table 1. On the MoCA memory 
measure, participants scored a mean of 3.2 with a standard deviation of 1.3, revealing that 
they recalled over half of the words presented to them on average. Participants correctly 
repeated sequences in the MoCA attention measure 66% of the time, and the mean score 
on the MOS-HIV CF4 was 68.8 out of 100 with a standard deviation of 18.9. 
 
 
 
 
Figure 5. Distributions and Frequencies for Dependent Variables (Measures of 
Cognitive Dysfunction)  
Left Graph: Distribution of MoCA Memory Score, with the score (1-5) listed on the X-
axis and the percent of the sample listed on the Y-axis.  
Right Graph: MOS-HIV CF4 Score (1-100) listed on the X-axis and the percent of the 
sample listed on the Y-axis.  
Bottom table: Frequencies and percentages from the MoCA attention score dichotomized 
for scoring of either 0 or 1 or 2.  
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Results of Regression analyses  
 Out of the 8 different regression models fit, Group 1, Group 5, and Group 6 
revealed significant associations between the independent and dependent variables.  
 In Group 1, we used unadjusted, core-adjusted, and fully-adjusted regression 
models to test the association between current marijuana use all three cognitive 
outcomes. Current marijuana use was significantly associated with the MOS-HIV CF4 
score, but neither the MoCA memory or MoCA attention scores as shown in Table 3 
below.  
 
 
Table 3. Significant Association Between Current Marijuana Use and MOS-HIV 
CF4 Score  
Table 3 shows the p-values, confidence intervals, β-values, and odds ratios for the Group 
1 regression analyses using unadjusted, core-adjusted, and fully-adjusted models. Linear 
regression was used for the MOS-HIV CF4 and MoCA memory outcomes and logistic 
regression was used for the MoCA attention outcome. Current marijuana use was 
significantly negatively associated with the MOS-HIV CF4 score in the core-adjusted and 
fully-adjusted models.  
 
 
 
Group 1: Independent Variable: Current Marijuana (# days Marijuana was used 
in the past 30 days)  
Dependent 
Variables 
Unadjusted Core-Adjusted Fully-Adjusted 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
MOS-HIV 
CF4 Score 
(range 1-
100) 
0.3 -0.4, 0.1 -0.1 0.03 -0.5, -0.02 -0.2 0.01 -0.5, -0.07 -0.30 
MoCA 
Memroy 
Score 
0.4 -0.01, 0.02 0.007 0.8 -0.01, 0.02 0.002 0.8 -0.01. 0.02 0.002 
MoCA 
Attention 
Score 
0.4 0.9, 1.0 Odds 
Ratio 
0.4 0.9, 1.0 Odds 
Ratio 
0.3 0.9, 1.0 Odds 
Ratio 
1.0 1.0 1.0 
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 In Group 2, we used unadjusted, core-adjusted, and fully-adjusted regression 
models to test the association between current heavy alcohol use and all three cognitive 
outcomes. No significant associations were found between current heavy alcohol use and 
any of the cognitive outcomes as shown in Table 4 below.  
 
Table 4. No Association between Current Heavy Drinking and Cognitive Outcomes  
Table 4 shows the p-values, confidence intervals, β-values, and odds ratios for the Group 
2 regression analyses using unadjusted, core-adjusted, and fully-adjusted models. Linear 
regression was used for the MOS-HIV CF4 and MoCA memory outcomes and logistic 
regression was used for the MoCA attention outcome. No significant associations were 
found between current heavy drinking and any cognitive outcome.  
 
 
Group 2: Independent Variable: Current Heavy Drinking (# heavy drinking days 
in the past 30 days)  
Dependent 
Variables 
Unadjusted Core-Adjusted Full-Adjusted 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
MOS-HIV 
CF4 Score 
(range 1-
100) 
0.7 -0.2, 0.4 0.06 0.3 -0.1, 0.4 0.1 0.2 -0.09, 0.6 0.2 
MoCA 
Memroy 
Score 
0.3 -0.03, 0.01 -0.01 0.6 -0.03, 0.02 -
0.005 
0.6 -0.02, 0.02 -
0.006 
MoCA 
Attention 
Score 
0.8 0.9, 1.0 Odds 
Ratio 
0.6 0.5, 1.05 Odds 
Ratio 
0.7 0.9, 1.01 Odds 
Ratio 
1.0 1.0 1.0 
 
 In Group 3, we used unadjusted, core-adjusted, and fully-adjusted regression 
models to test the association between lifetime marijuana use and all three cognitive 
outcomes. No significant associations were found between lifetime marijuana use and 
any cognitive outcome as shown in Table 5 below.  
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Table 5.  No Association between Lifetime Marijuana Use and Cognitive Outcomes  
Table 5 shows the p-values, confidence intervals, β-values, and odds ratios for the Group 
3 regression analyses using unadjusted, core-adjusted, and fully-adjusted models. Linear 
regression was used for the MOS-HIV CF4 and MoCA memory outcomes and logistic 
regression was used for the MoCA attention outcome. Lifetime marijuana use was not 
significantly associated with any cognitive outcome.   
 
 
Group 3: Independent Variable: Lifetime Marijuana Use (# years marijuana was 
used ≥ 3 times per week)  
Dependent 
Variables 
Unadjusted Core-Adjusted Full-Adjusted 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
MOS-HIV 
CF4 Score 
(range 1-
100) 
0.9 -0.2, 0.2 0.01 0.1 -0.3, 0.05 -0.1 0.2 -0.3, 0.06 -0.1 
MoCA 
Memroy 
Score 
0.1 -0.002, 
0.03 
0.01 0.2 -0.006, 
0.02 
0.009 0.2 -0.005, 
0.03 
-
0.005 
MoCA 
Attention 
Score 
0.2 1.0, 1.04 Odds 
Ratio 
0.2 0.9, 1.0 Odds 
Ratio 
0.2 1.0, 1.05 Odds 
Ratio 
1.0 1.0 1.0 
 
 In Group 4 we used unadjusted, core-adjusted, and fully-adjusted regression 
models to test the association between lifetime alcohol use in kilograms and all three 
cognitive outcomes. No significant associations were found between lifetime alcohol use 
(kg) and any cognitive outcome as seen below in Table 6.  
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Table 6. No Association between Lifetime Alcohol Use (Kg) and Cognitive Outcomes  
Table 6 shows the p-values, confidence intervals, β-values, and odds ratios for the Group 
3 regression analyses using unadjusted, core-adjusted, and fully-adjusted models. Linear 
regression was used for the MOS-HIV CF4 and MoCA memory outcomes and logistic 
regression was used for the MoCA attention outcome. Lifetime alcohol use measured in 
Kg was not significantly associated with any cognitive outcome.  
 
 
Group 4: Independent Variable: Lifetime Alcohol Use (Total Kg)  
Dependent 
Variables 
Unadjusted Core-Adjusted Full-Adjusted 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
MOS-HIV 
CF4 Score 
(range 1-
100) 
0.8 -0.003, 
0.002 
-
0.0004 
0.9 -0.002, 
0.002 
-0.002 1.0 -0.002, 
0.002 
0 
MoCA 
Memroy 
Score 
0.6 -0.0001, 
0.002 
0 0.2 -0.0001, 
0.0003 
0.0001 0.3 -0.0001, 
0.0003 
0.0001 
MoCA 
Attention 
Score 
0.7 1.0, 1.0 Odds 
Ratio 
0.9 1.0, 1.0 Odds 
Ratio 
0.8 1.0, 1.0 Odds 
Ratio 
1.0 1.0 1.0 
 
 In Group 5 we used unadjusted, core-adjusted, and fully-adjusted regression 
models to test the association between lifetime marijuana use, duration of heavy drinking 
(years), current marijuana use, and current heavy alcohol use and each cognitive outcome 
adjusting for all covariates. Current marijuana use was again significantly associated with 
the MOS-HIV CF4 score, but neither MoCA score. Current heavy alcohol use was also 
significantly associated with the MOS-HIV CF4 score in this model, but it was in the 
opposite direction of what was hypothesized. Current heavy alcohol use was not 
associated with either MoCA score. Likewise lifetime marijuana and heavy alcohol use 
were not associated with any cognitive outcome. See Table 7 below.  
 
 
51 
Table 7. Significant Associations between Current Marijuana, Heavy Alcohol Use 
(kg) and the MOS-HIV CF4 Score 
Table 7 shows the p-values, confidence intervals, β-values, and odds ratios for the Group 
3 regression analyses using unadjusted, core-adjusted, and fully-adjusted models. Linear 
regression was used for the MOS-HIV CF4 and MoCA memory outcomes and logistic 
regression was used for the MoCA attention outcome. Current marijuana and heavy 
alcohol use (kg) were both significantly associated with the MOS-HIV CF4 score, with 
current marijuana having a negative association and current heavy drinking having a 
positive association.  Both were only significant in the fully adjusted model. Duration of 
heavy drinking and lifetime marijuana use were not significantly associated with any 
cognitive outcome. First, second, third, and fourth values in the table correspond to 
lifetime marijuana, duration of heavy drinking (years), current marijuana use, and current 
heavy drinking  
 
 
 
Group 5: Independent Variables: Lifetime Marijuana use, duration of heavy 
drinking (years),  current marijuana use and current heavy drinking 
Dependent 
Variables 
Unadjusted Core-Adjusted Full-Adjusted 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
MOS-HIV 
CF4 Score 
(range 1-
100) 
0.4 
0.5 
0.4 
0.2 
-0.1, 0.4 
-0.4, 0.2 
-0.2, 0.5 
-0.5, 0.09 
0.1 
-0.09 
0.1 
-0.2 
0.8 
0.3 
0.08 
0.05 
-0.3, 0.2 
-0.4, 0.1 
-0.03, 0.6 
-0.5, -0.003 
-0.03 
-0.1 
0.3 
-0.3 
0.8 
0.2 
0.03 
0.01 
-0.2, 0.3 
-0.5, 0.1 
0.03, 0.7 
-0.6, -0.08 
0.03 
-0.2 
0.4 
-0.4 
MoCA 
Memroy 
Score 
0.2 
0.3 
0.1 
0.8 
-0.007, 0.03 
-0.009, 0.03 
-0.04, 0.006 
-0.02, 0,02 
0.01 
0.01 
-0.02 
0.003 
 
0.3 
0.007 
0.2 
0.8 
-0.008, 0.03 
-0.002, 0.04 
-0.04, 0.009 
-0.02, 0.02 
0.01 
0.02 
-0.01 
-0.002 
0.2 
0.2 
0.3 
0.7 
-0.006, 0.03 
-0.008, 0.04 
-0.04, 0.01 
-0.03, 0.02 
0.01 
0.01 
-0.01 
-0.004 
MoCA 
Attention 
Score 
0.3 
0.7 
0.9 
0.9 
1.0, 1.05,  
1.0, 1.04 
1.0, 1.04,  
1.0, 1.04 
Odds 
Ratio 
0.4 
0.2 
0.8 
0.7 
1.0, 1.05 
1.0, 1.06 
1.0, 1.04 
1.0, 1.05 
Odds 
Ratio 
0.3 
0.5 
1.0 
0.8 
1.0, 1.06 
1.0, 1.05 
1.0, 1.05 
1.0, 1.01 
Odds 
Ratio 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
 
 In Group 6 we used unadjusted, core-adjusted, and fully-adjusted regression 
models to test the association of lifetime marijuana use, lifetime heavy alcohol use 
measured in kg, current marijuana use, and current heavy alcohol use and each cognitive 
outcome adjusting for all covariates. Again, current marijuana use was significantly 
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associated with the MOS-HIV CF4 score but neither the MoCA memory or MoCA 
attention scores. Current heavy drinking, lifetime marijuana use, and lifetime heavy 
alcohol use (kg) were not significantly associated with any cognitive outcomes. See 
Table 8 below.  
 
Table 8. Significant Association Between Current Marijuana Use and MOS-HIV 
CF4 Score  
 
Table 8 shows the p-values, confidence intervals, β-values, and odds ratios for the Group 
3 regression analyses using unadjusted, core-adjusted, and fully-adjusted models. Linear 
regression was used for the MOS-HIV CF4 and MoCA memory outcomes and logistic 
regression was used for the MoCA attention outcome. Current marijuana use was 
significantly negatively associated with the MOS-HIV CF4 score in only the fully-
adjusted model. Current heavy drinking, lifetime marijuana use, and lifetime heavy 
alcohol use (kg) were not significantly associated with any cognitive outcome. First, 
second, third, and fourth values in the table correspond to lifetime marijuana, duration of 
heavy drinking (years), current marijuana use, and current heavy drinking 
 
 
Group 6: Independent Variables: lifetime marijuana use, lifetime heavy alcohol use 
(Kg), current marijuana use, and current heavy drinking 
Dependent 
Variables 
Unadjusted Core-Adjusted Full-Adjusted 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
p-
Value 
Confidence 
Interval 
(95%) 
β- 
Value 
MOS-HIV 
CF4 Score 
(range 1-
100) 
0.4 
0.5 
0.4 
0.2 
-0.1, 0.4 
-0.003, 
0.002 
-0.2, 0.5 
-0.5, 0.09 
 
0.1 
-
0.0008 
0.1 
-0.1 
0.8 
0.5 
0.09 
0.05 
-0.3, 0.2 
-0.003, 
0.001 
-0.05, 0.6 
-0.5, 0.0007 
-0.03 
-
0.0008 
0.3 
-0.3 
0.8 
0.5 
0.05 
0.01 
-0.2, 0.3 
-0.003, 
0.002 
-0.006, 0.6 
-0.6, -0.07 
0.03 
-0.008 
0.3 
-0.4 
MoCA 
Memroy 
Score 
0.2 
0.4 
0.2 
0.8 
-0.007, 0.03 
-0.0001, 
0.0003 
-0.04, 0.007 
-0.02, 0.02 
0.01 
0.0001 
-0.02 
0.003 
0.2 
0.2 
0.3 
0.8 
-0.008, 0.03 
0, -0.0003 
-0.03, 0.01 
-0.02, 0.02 
0.01 
0.0001 
-0.01 
-0.003 
0.2 
0.2 
0.3 
0.7 
-0.007, 0.03 
-0.0001, 
0.0003 
-0.04, 0.01 
-0.03, 0.02 
0.01 
0.0001 
-0.01 
-0.005 
MoCA 
Attention 
Score 
0.3 
0.6 
0.7 
0.9 
1.0, 1.05 
1.0, 1.00 
1.0, 1.05 
1.0, 1.04 
Odds 
Ratio 
0.3 
0.9 
0.7 
0.9 
1.0, 1.05 
1.0, 1.00 
1.0, 1.05 
1.0, 1.04 
Odds 
Ratio 
1.3 
0.7 
0.7 
0.9 
1.0, 1.1 
1.0, 1.0 
1.0, 1.1 
1.0, 1.05 
Odds 
Ratio 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
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In Group 7, we used unadjusted, core-adjusted, and fully-adjusted regression models to 
determine if there was an interaction between current marijuana and heavy alcohol use on 
all three cognitive outcomes. Likewise, in Group 8, we used unadjusted, core-adjusted, 
and fully-adjusted regression models to determine if there was an interaction between 
lifetime marijuana and heavy alcohol use (kg) on all three cognitive outcomes. There 
were no significant interactions found between current or lifetime marijuana and heavy 
alcohol use with any measure of cognitive dysfunction.  
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DISCUSSION 
 
 We examined the effects of marijuana and heavy alcohol use on cognitive 
function in people with HIV-infection. Regression analyses revealed a significant, 
negative association between current marijuana use and the MOS-HIV CF4 score. A 
significant positive association between current heavy drinking and the MOS-HIV CF4 
score was also found, but was in the opposite direction of what was expected. Current 
marijuana use was not associated with either the MoCA memory or MoCA attention 
score. Likewise, we did not find any associations between lifetime marijuana or either 
measure of lifetime heavy alcohol use and any measures of cognitive dysfunction. There 
were no interactions between current marijuana and heavy alcohol use or lifetime 
marijuana and heavy alcohol use with any cognitive outcome.  
Our finding that current marijuana use has a negative impact on cognitive 
function is consistent with other reports in the literature that acute use of marijuana has 
negative effects on memory, executive function, and attention with some residual effects 
reported in the same cognitive domains27-29,33,40-45,48. Similarly, the results that current, 
but not lifetime, marijuana use is associated with cognitive dysfunction are consistent 
with previous findings indicating that any effects of marijuana use diminish or are absent 
after around a month of abstinence, and that the long-term persistent effects of marijuana 
on cognition are still under debate40,42,43,51. Over 55% of participants reported no 
marijuana use in the past 30 days, indicating that many had abstained for at least one 
month. This would theoretically be enough time for most cognitive impairments to 
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subside. It is believed that after abstinence of one month, all cognitive impairments 
caused by marijuana will remit42,43. Therefore, it is possible that our lifetime marijuana 
measure was not associated with any cognitive dysfunction because a good portion of our 
study population had abstained for a long enough period of time for cognitive 
dysfunction to abate.  
On the other hand, our finding that current heavy drinking is associated with an 
increase in cognitive function is inconsistent with the literature. Heavy alcohol use has 
been shown to have negative effects on executive function, attention, and 
memory53,60,61,66. While these findings could be causal (some studies have found that 
moderate drinking at low levels is associated with better cognitive function104-107), this 
finding most likely represents a Type I error or a failure to adequately adjust for 
confounders. This finding also only appears in the Group 5 multivariable regression 
model (whereas the finding that current marijuana is associated with cognitive 
dysfunction appears in 3 models) revealing that it is not very robust.  
In general, it is well documented that what may be considered hazardous exposure 
to alcohol over long periods of time can lead to severe cognitive deficits such as ARD 
and WKS. In a review of cognitive functioning among sober, social drinkers, Parksons et 
al found that 5-6 standard drinks per day over time created some cognitive deficits, 7-9 
drinks per day caused mild cognitive deficits, and 10 or more drinks per day caused 
cognitive deficits such as those seen in individuals with alcohol use disorders109. These 
levels of drinking are consistent with hazardous drinking as defined in the current study. 
However, the threshold at which alcohol consumption becomes harmful is unclear and 
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most-likely variable from person to person, with the effects on cognition potentially U-
shaped in nature meaning low amounts of alcohol can be beneficial and high amounts 
harmful101,108. Therefore, we may have not detected any significant associations of 
lifetime alcohol use and cognitive dysfunction despite individuals drinking at hazardous 
levels due to the fact that the effects of alcohol on cognition are variable and cognitive 
dysfunction may not be occurring in all participants even when exposed to alcohol at that 
level.    
Despite marijuana, alcohol, and HIV-infection having their main affects on 
different areas of the brain, certain similarities would indicate that synergistic effects 
could be encountered, but this was not found in our study. HIV-infection, marijuana use, 
and alcohol use have all been shown to affect the basal ganglia and frontal lobes, which 
are involved in executive functions1,9-11,20,26,27,54,59. The HIV-virus as well as the CB1 
receptor, which binds ∆9-THC, have been shown to have the highest concentration in the 
basal ganglia1,9-11,20,26,27. Likewise, there has been shown to be an increase in MCP-1, a 
measure of inflammation in the brains of alcoholics, in the basal ganglia59. This suggests 
that there is a potential for marijuana, alcohol, and HIV to have negative synergistic 
effects on the basal ganglia and frontal cortices, manifesting as deficits in executive 
function, but this was not found in the present study. Likewise, hippocampal damage has 
been reported in the brains of alcoholics, and the CB1 receptor has been shown to induce 
hippocampal cell death, also suggesting a synergistic effect of these two on perhaps 
memory function27.  
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It is well documented that marijuana causes deficits in recall, manifesting as acute 
and residual cognitive dysfunction27-29,31,33,35. The MoCA directly tests recall, as 
participants must recall a list of words directly after hearing them, and five minutes later, 
so the finding that current and lifetime marijuana use was not associated with it is 
opposite of what was expected. One reason for this, and a limitation of our study, may 
have been that the MoCA as a whole has been validated for use in HIV-infected people, 
but its domains have only been validated in populations such as individuals with varying 
forms of dementia.  The domains individually may not be sensitive enough to test mild 
cognitive dysfunction among specific domains of cognition in those with HIV-infection 
and comorbid substance use. This may also be why there was no association found 
between the MoCA attention score and recent marijuana use, since there is also some 
support to show that acute marijuana use impairs attentional function28,29.  The MOS-HIV 
takes executive function into consideration (as well as attention and memory) which is 
known to be impaired in HIV-infection and to some extent with marijuana use1,9-
11,21,28,29,33. Current marijuana use showed a significant correlation with the MOS-HIV but 
neither MoCA score, which may be reflective of the MOS-HIV being more sensitive to 
executive function impairment and more global cognitive dysfunction in general.  
On the other hand, a strength of this study was that we included many covariates 
in the analyses to adjust for potential confounders. All of these variables have been 
shown to influence cognition in their own right1,7,10,12,13,22. Similarly, since we fit a 
variety of different multivariable regression models, we were able to see that the 
association between number of days of marijuana use in the past 30 days and MOS-HIV 
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CF4 score was found in all models in which it was included, suggesting that it was a very 
robust association not accounted for by any of the confounding factors we measured and 
adjusted for.  
 Since the MOS-HIV in general is utilized as a brief screening tool to assess 
functional status and well-being in those with HIV-infection, our findings suggest that 
increasing current marijuana use may actually decrease an individual’s level of 
functioning and well-being. We found that for every day that an individual uses 
marijuana, their MOS-HIV CF4 score decreases by 0.3 points. This is significant since 
optimal daily functioning is necessary for optimal HIV suppression. Therefore, even if 
marijuana may have proven therapeutic qualities, they will need to be weighed against 
the risks of cognitive dysfunction.  
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CONCLUSION 
 
In summary, current marijuana use appears to be associated with lower cognitive 
function. We did not find an association between lifetime marijuana use and any measure 
of cognitive dysfunction, nor did we find an association with lifetime alcohol use and any 
measure of cognitive dysfunction. Current alcohol use was associated with better 
cognitive function, but this was opposite of what we hypothesized. Likewise, no 
interactions were found between current marijuana use and heavy drinking on cognitive 
function or between lifetime marijuana use and lifetime heavy drinking on cognitive 
function. Future research should utilize measures more specific to HIV-infected people as 
well as measures that are sensitive to more subtle forms of cognitive dysfunction and 
possibly a wider range of cognitive dysfunction other than that of memory and attention. 
Future studies should also consider whether or not the effects of alcohol and marijuana 
are detectable as significant agents of cognitive decline in individuals who have many 
competing risks for cognitive dysfunction.  
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APPENDIX A 
30 Day Drug ASI 
 
Now I am going to ask you some questions about your use of drugs in the past 30 days:  
 
Note to Interviewer: Record numbers of days subject reported using non-prescription drugs (i.e., heroin, 
methamphetamine) and numbers of days subject reported using prescription drugs used without a doctor’s 
prescription of in amounts greater than prescribed.  
 
Note the usual or most recent route of administration for each drug. For more than one route, choose the 
most severe. The routes are listed from least severe to most severe. Ask if subject is currently prescribed 
each prescription drug/category after assessing number of days of misuse and route of administration for 
all drugs.  
 
How many days in the past 30 days have you used…?  
 
            Number of Days               Route of Administration 
         (Oral, Nasal, Smoking, Injection, IV) 
Cocaine                                ________                               ________ 
   
Heroin     ________                               ________ 
 
Hallucinogens    ________                               ________ 
 
Phencyclidines     ________                               ________ 
 
Cannabis/        Are you Currently 
Marijuana    ________                               ________                Prescribed…?  
 
Stimulants/        ☐ Yes  ☐ No  
Amphetamines    ________                               ________ 
  
Buprenorphine    ________                               ________     ☐ Yes  ☐ No 
 
Methadone    ________                               ________  ☐ Yes  ☐ No  
 
Other Prescription   ________                               ________  ☐ Yes  ☐ No 
Opioids 
 
Tranquilizers/    ________                               ________  ☐ Yes  ☐ No 
Sedatives 
 
Inhalants    ________                               ________ 
 
Miscellaneous    ________                               ________ 
 
More than  
One Drug     ________                               ________ 
 
No Drugs    ________                               ________ 
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APPENDIX B 
30-Day TLFB Alcohol 
 
Interviewer Prompt: Administer TLFB 
Use a calendar for the preceding 30 days starting from yesterday, to recor the subject’s 
use of alcohol.  
 
If alcohol is used, record the number of standard drinks for each day. Consider a “drink” 
to be a can or bottle of beer (12 ounces), a glass of wine (5 ounces), a wine cooler (12 
ounces), or a shot of hard liquor like gin, vodka, or whiskey (1.5 ounces).  
 
Please enter the number of drinks per day rounded to the nearest whole number. The 30th 
day on the Timeline Follow-Back should be entered as Day 1. “Yesterday” (i.e. the day 
prior to the date the TLFB was administered) should be recorded as Day 30.  
 
Day 
Alcohol Use 
Number of Drinks 
Day 
Alcohol Use 
Number of Drinks 
Day 1 
 
 Day 16  
Day 2 
 
 Day 17  
Day 3 
 
 Day 18  
Day 4 
 
 Day 19  
Day 5 
 
 Day 20  
Day 6 
 
 Day 21  
Day 7 
 
 Day 22  
Day 8 
 
 Day 23  
Day 9 
 
 Day 24  
Day 10 
 
 Day 25  
Day 11 
 
 Day 26  
Day 12 
 
 Day 27  
Day 13 
 
 Day 28  
Day 14 
 
 Day 29  
Day 15 
 
 Day 30  
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APPENDIX C 
 
Lifetime ASI 
 
This next section will focus on questions about your alcohol and/or drug use. By “drug use” we mean 
drugs that you use either without a doctor’s prescription, in larger amounts that prescribed, or for 
longer periods that prescribed.  
 
Note the usual or most recent route of administration for each drug. For more than one route, choose the 
most severe. The routes are listed from least to most severe: Oral, Nasal, Smoking, Injection, IV  
 
How many years in your life have you regularly used…? (3x/week or more) 
How do you use it?  
How old were you the first time you used…?  
 
       Lifetime Use: ≥ 3x/week       Route of Administration           Age of Onset 
                        (Number of Years)      
Cocaine                                ________                               ________          ________ 
 
Heroin     ________                               ________          ________ 
     
Hallucinogens    ________                               ________          ________ 
 
Phencyclidines     ________                               ________          ________ 
 
Cannabis/         
Marijuana    ________                               ________          ________ 
 
Stimulants/          
Amphetamines    ________                               ________         ________ 
 
Buprenorphine    ________                               ________            ________  
  
Methadone    ________                               ________               ________   
 
Other Prescription   ________                               ________         ________ 
Opioids 
 
Tranquilizers/    ________                               ________         ________ 
Sedatives 
 
Inhalants    ________                               ________         ________ 
 
Miscellaneous    ________                               ________         ________ 
 
More than  
One Drug     ________                               ________         ________ 
    
No Drugs    ________                               ________         ________ 
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APPENDIX D 
Lifetime Drinking History 
I’m going to ask you about your drinking history. I’d like to start with the year that you began to 
drink regularly and work forward to the present. Please give me information as accurately as you 
can about what type of beverage you were drinking, how much, and how often.  
Note to interviewer: Why the timing overlaps with the age that the subject found out that they were HIV-
infected, ask question B. Continue through phases until current phase is reached. Use additional forms as 
needed 
How old were you the first time you had a drink? By “first drink” I mean the first full drink of 
alcohol excluding tastes or small sips.  
  ______ (age in years) 
  ☐  Never had a drink SKIP TO NEXT SECTION   
 
Phase 1 of Drinking 
Now I am going to ask you about your drinking during the first year that you began to have at least 
one drink per month. Consider a “drink” to be a 12oz can or a bottle of beer, a 5oz glass of wine, a 
120z wine cooler, or a 1.5oz shot of hard liquor (like scotch, gin, or vodka).  
1A. How old were you when you began to drink at least one drink per month (regular drinking?)  
 ______ Age of phase 1 of drinking (years) 
 ☐  Never had more than one drink SKIP TO NEXT SECTION  
1B. How many drinks would you have on a typical day when you were drinking?  
 ______ typical # of drinks/day (quantity)  
(If participant answers in anything other than # of drinks, convert later)  
1C. How many days per month would you generally drink at this level (i.e. typical # of drinks)?  
 ______ days/month (frequency) 
1D. What is the maximum number of drinks that you would have in any one day?  
 ______ maximum # of drinks/day (quantity)  
(This is the maximum # of drinks the subject actually drank, not his/her potential. If participant answers in 
quantity other than # of drinks, convert later)  
You just told me about your drinking habits at the point when you first began to drink regularly. 
You said you began to drink when you were ______ years old, that you typically drank ______ drinks 
per occasion, ______ times per month.  
EVENT that changed drinking 
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Now I want you to think about when your drinking behavior changed in a significant way from this 
time. This change in your drinking might have occurred 6 months after you started drinking 
regularly or perhaps 2 or 5 years later. Can you think of any event or events in your life that may 
have changed your drinking habits? Examples of events could be the death of someone close to you, 
marital or family problems, medical problems, jail, or any other event that affected your drinking.  
Event that changed subject’s drinking pattern: ______________ 
1E/2A. How old were you when this event happened, and your drinking changed?  
 ______ age when drinking changed (years)  
 
Phase 2 of Drinking 
2B. After this event or events happened, and your drinking changed, how many drinks would you 
have on a typical day when you were drinking?  
 ______ typical # of drinks/day (quantity) 
2C. How many days per month would you generally drink at this level (typical # of drinks)?  
 ______ days/month (frequency)  
2D. What is the maximum number of drinks that you would have in any one day?  
 ______ maximum # drinks/day (quantity)  
(This is the maximum # of drinks the subject actually drank, not his/her potential) 
How long did you continue to drink at this level (on average ______ drinks per day, ______ days a 
month) until your drinking changed in a significant way? Did any important event or events occur 
during this period that changed your usual drinking habits? Examples of events could be the death of 
someone close to you, marital or family problems, work problems, medical problems, jail, or any 
other event that affected your drinking.  
Even that changed subject’s drinking pattern: ________________ 
2E/3A. How old were you when this event happened, and your drinking changed?  
 ______ age when drinking changed (years)  
 
Phase 3 of Drinking  
3B. After this even or events happened, and your drinking changed, how many drinks would you 
have on a typical day when you were drinking?  
 ______ typical # of drinks/day (quantity)  
3C. How many days per month would you generally drink at this level (typical # of drinks)?  
 ______ days/month (frequency)  
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3D. What is the maximum number of drinks that you would have in any one day?  
 ______ maximum # drinks/day (quantity)  
(This is the maximum # of drinks the subject actually drank, not his/her potential) 
How long did you continue to drink at this level (on average ______drinks per day ______ days a 
month) until your drinking changed in a significant way? Did any important event or events occur 
during this period that changed your usual drinking habits?  
Event that changed subject’s drinking pattern: _____________  
3E/4A. How old were you when this even happened, and your drinking changed?  
 ______ age when drinking changed (years)  
 
Phase 4 of Drinking  
4B. After this even or events happened, and your drinking changed, how many drinks would you 
have on a typical day when you were drinking?  
 ______ typical # of drinks/day (quantity)  
4C. How many days per month would you generally drink at this level (typical # of drinks)?  
 ______ days/month (frequency)  
4D. What is the maximum number of drinks that you would have in any one day?  
 ______ maximum # drinks/day (quantity)  
(This is the maximum # of drinks the subject actually drank, not his/her potential) 
How long did you continue to drink at this level (on average ______drinks per day ______ days a 
month) until your drinking changed in a significant way? Did any important event or events occur 
during this period that changed your usual drinking habits?  
Event that changed subject’s drinking pattern: _____________  
4E/5A. How old were you when this even happened, and your drinking changed?  
 ______ age when drinking changed (years)  
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Phase 5 of Drinking  
5B. After this even or events happened, and your drinking changed, how many drinks would you 
have on a typical day when you were drinking?  
 ______ typical # of drinks/day (quantity)  
5C. How many days per month would you generally drink at this level (typical # of drinks)?  
 ______ days/month (frequency)  
5D. What is the maximum number of drinks that you would have in any one day?  
 ______ maximum # drinks/day (quantity)  
(This is the maximum # of drinks the subject actually drank, not his/her potential) 
How long did you continue to drink at this level (on average ______drinks per day ______ days a 
month) until your drinking changed in a significant way? Did any important event or events occur 
during this period that changed your usual drinking habits?  
Event that changed subject’s drinking pattern: _____________  
5E/6A. How old were you when this even happened, and your drinking changed?  
 ______ age when drinking changed (years)  
 
Phase 6 of Drinking  
6B. After this even or events happened, and your drinking changed, how many drinks would you 
have on a typical day when you were drinking?  
 ______ typical # of drinks/day (quantity)  
6C. How many days per month would you generally drink at this level (typical # of drinks)?  
 ______ days/month (frequency)  
6D. What is the maximum number of drinks that you would have in any one day?  
 ______ maximum # drinks/day (quantity)  
(This is the maximum # of drinks the subject actually drank, not his/her potential) 
How long did you continue to drink at this level (on average ______drinks per day ______ days a 
month) until your drinking changed in a significant way? Did any important event or events occur 
during this period that changed your usual drinking habits?  
Event that changed subject’s drinking pattern: _____________  
6E/7A. How old were you when this even happened, and your drinking changed?  
 ______ age when drinking changed (years)  
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Phase 7 of Drinking  
7B. After this even or events happened, and your drinking changed, how many drinks would you 
have on a typical day when you were drinking?  
 ______ typical # of drinks/day (quantity)  
7C. How many days per month would you generally drink at this level (typical # of drinks)?  
 ______ days/month (frequency)  
7D. What is the maximum number of drinks that you would have in any one day?  
 ______ maximum # drinks/day (quantity)  
(This is the maximum # of drinks the subject actually drank, not his/her potential) 
How long did you continue to drink at this level (on average ______drinks per day ______ days a 
month) until your drinking changed in a significant way? Did any important event or events occur 
during this period that changed your usual drinking habits?  
Event that changed subject’s drinking pattern: _____________  
7E/8A. How old were you when this even happened, and your drinking changed?  
 ______ age when drinking changed (years)  
 
Phase 8 of Drinking  
8B. After this even or events happened, and your drinking changed, how many drinks would you 
have on a typical day when you were drinking?  
 ______ typical # of drinks/day (quantity)  
8C. How many days per month would you generally drink at this level (typical # of drinks)?  
 ______ days/month (frequency)  
8D. What is the maximum number of drinks that you would have in any one day?  
 ______ maximum # drinks/day (quantity)  
(This is the maximum # of drinks the subject actually drank, not his/her potential) 
How long did you continue to drink at this level (on average ______drinks per day ______ days a 
month) until your drinking changed in a significant way? Did any important event or events occur 
during this period that changed your usual drinking habits?  
Event that changed subject’s drinking pattern: _____________  
8E/9A. How old were you when this even happened, and your drinking changed?  
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 ______ age when drinking changed (years)  
 
LDH WEB FORM FOR DATA ENTRY  
Note to Interviewer: Record age of first drink in the table below. Beginning with the earliest phase, record 
the subject’s age when this phase of drinking began and ended, the typical number of drinks the subject 
reported having per occasion (drinking day), the average number of days per month the subject reported 
drinking at this level (i.e. typical number of drinks) and the maximum number of drinks the subject reported 
having in any one day. Record this information in below for each phase of drinking reported by the subject.  
Age Range (younger to older)           Frequency (days/month)              Quantity (drinks/day)  
First drink: ______ 
0. OR  
☐ Never had a drink  
From age: ______ 
1A. OR  
☐ Never had more than one           1C. ______ days/month                   1B. Typical # drinks/day______   
drink a month  
 
1E. To age:      ______      1D. Maximum # drinks/day: ___ 
2A. From age: ______      2B. Typical # drinks/day: ______ 
    2C. ______ days/ month  
2E. To age:      ______       2D. Maximum # drinks/day: ___ 
3A. From age:  ______       3B. Typical # drinks/day: ______ 
    3C. ______ days/ month  
3E. To age:      ______       3D. Maximum # drinks/day: ___ 
4A. From age:  ______       4B. Typical # drinks/day: ______  
    4C. ______ days/ month  
4E. To age:       ______       4D.  Maximum # drinks/day: ___ 
5A. From age:   ______       5B. Typical # drinks/day: ______ 
    5C. ______ days/ month 
5E. To age:       ______       5D.  Maximum # drinks/day: ___ 
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6A. From age:   ______      6B. Typical # drinks/day: ______  
    6C. ______ days/ month 
6E. To age:        ______      6D. Maximum # drinks/day: ___ 
 
7A. From age:    ______      7B. Typical # drinks/day: ______  
    7C. ______ days/ month 
7E. To age:        ______      7D. Maximum # drinks/day: ___ 
8A. From age:   ______       8B. Typical # drinks/day: ______  
    8C. ______ days/ month  
8E. To age:        ______      8D.  Maximum # drinks/day: ___ 
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APPENDIX E 
MoCA Memory and Attention Sections 
 
1. Memory:  
 To Interviewer: Read list of words at the rate of 1 per second. Subject 
 must repeat them. Do 2 trials, even if the first trial is successful. You will 
 ask the subject to recall again after the next section. Mark a check in the  
 allocated space for each word the subject produces on this first trial.  
 When the subject indicates that (s)he has finished (has recalled all words),  
 or can recall no more words, read the list a second time giving the  
 following instructions:  
  
 A. This is a memory test. I am going to read a list of words that you  
 will have to remember now and later on. Listen carefully. When I  
 am through, tell me as many words as you can remember. It doesn’t 
 matter in what order you say them.  
  
  
 B. I am going to read the same list for a second time. Try to  
 remember and tell me as many words as you can, including 
 words you said the first time 
  
 To Interviewer: Put a check in the allocated space for each word the  
 subject recalls after the second trial. At the end of the second trial,  
 inform the subject that (s)he will be asked to recall these words again  
 by saying:  
 
 I will ask you to recall those words again in about 5 minutes.  
 
 
2. Attention:  
 A. I am going to say some numbers and when I am through, repeat  
 them to me exactly as I said them.  
  
 To Interviewer: Read the five number sequence at a rate of one digit  
 FACE VELVET CHURCH DAISY RED 
1st Trial      
 FACE VELVET CHURCH DAISY RED 
2nd 
Trial 
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per second 
 
2 1 8 5 4 
 
Score:  0 or  1 
 
B. Now I am going to say some more numbers, but when I am through 
you must repeat them to me in the backwards order.  
 
To interviewer: Read the three number sequence at a rate of one digit per 
second. Subject has to repeat them in backward order 
 
7 4 2 
 
Score:  0 or 1 
 
Scoring: Allocate one point for each sequence correctly repeated  
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APPENDIX F 
 
MOS-HIV CF4 (Taken from Section B of the Boston ARCH Baseline Screener) 
 
 
10. How much of the time during the past 4 weeks:  
 
a. Did you have difficulty reasoning and solving problems, for example, making plans, 
making decisions, learning new things?  
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 None of the time 
 Refused  
 
b. Did you forget things that happened recently, for example, where you put things and 
when you had appointments?  
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 None of the time 
 Refused  
 
c. Did you have trouble keeping your attention on any activity for long?  
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 None of the time 
 Refused  
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d. Did you have difficulty doing activities involving concentration and thinking?  
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 None of the time 
 Refused  
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LIST OF JOURNAL ABBREVIATIONS  
 
Addict Behav   Addictive Behaviors 
AIDS Behav   AIDS and Behavior  
AIDS Patient Care ST AIDS Patient Care and STDs 
Alcohol Clin Exp Res  Alcoholism- Clinical and Experimental Research  
Alcoholism Drug Depend Journal of Alcoholism and Drug Dependence  
Alcohol Res Health  Alcohol Research and Health  
Alzheimers Res Ther  Alzheimer’s Research and Therapy 
Am J Drug Alcohol Ab American Journal of Drug and Alcohol Abuse 
Am J Addict   American Journal on Addictions  
Am J Epidemiol  American Journal of Epidemiology  
Am J Psychiat   American Journal of Psychiatry 
Ann Neurol   Annals of Neurology 
Arch Gen Psychiat  Archives of General Psychiatry  
Behav Brain Res  Behavioral Brain Research  
Biol Psychiat   Biological Psychiatry  
Clin Neuropsychol  Clinical Neuropsychologist  
Curr Addict Rep  Current Addiction Reports  
Curr Drug Abuse Rev  Current Drug Abuse Reviews 
Curr HIV/AIDS Rep  Current HIV/AIDS Report 
Curr Opin Neurol  Current Opinion in Neurology 
Depress Anxiety  Depression and Anxiety  
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Drug Alcohol Depend  Drug and Alcohol Dependence  
Exp Clin Psychopharm Experimental and Clinical Psychopharmacology  
Exp Neurol   Experimental Neurology 
JAMA    JAMA: The Journal of the American Medical Association 
J Addict Med   Journal of Addiction Medicine  
J Am Geriatr Soc  Journal of American Geriatrics Society  
J AIDS Clinic Res  Journal of AIDS and Clinical Research  
J Acquir Immune Defic  Journal of Acquired Immune Deficiency Syndromes  
Syndr 
J Chron Dis   Journal of Chronic Diseases  
J Clin Epidemiol   Journal of Clinical Epidemiology  
J Clin Exp Neuropsychol Journal of Clinical and Experimental Neuropsychology  
J Clin Pharmacol  Journal of Clinical Pharmacology  
J Gerontol A Biol  Journals of Gerontology Series A- Biological Sciences 
    And Medical Sciences 
J Infect Dis   Journal of Infectious Diseases  
J Int Neuropsychol Soc Journal of the International Neuropsychological Society  
J Neuroimmune Phar  Journal of Neuroimmune Pharmacology  
J Neuropsychiatry Clin  Journal of Neuropscyhiatry and Clinical Neurosciences 
 Neurosci 
J Neurovirol   Journal of Neurovirology  
J Psychiatr Res  Journal of Psychiatric Research  
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J Pharmacol   Journal of Pharmacology 
J Stud Alcohol  Journal of Studies on Alcohol  
J Study Alcohol Drugs Journal of Studies on Alcohol and Drugs 
J Subst Abuse Treat  Journal of Substance Abuse Treatment  
Int J STD AIDS  International Journal of STDs and AIDS 
Medcare   Medical Care 
Neuropsychol Rev  Neuropsychology Review 
Pharmacol Biochem Be Pharmacology Biochemistry and Behavior  
Philos Trans R Soc Lond B  Philosophical Transactions of Royal Society London 
Biol Sci   Biological Society  
Prog Neurobiol  Progress in Neurobiology  
Psychol Addict Behav Psychology of Addictive Behaviors  
Psychpharmacology (Berl) Psychopharmacology (Berlin)  
Qual Life Res   Quality of Life Research  
Semin Neurol   Seminars in Neurology 
Sci Signal   Science Signaling  
Top Antivir Med  Topics in Antiviral Medicine 
 
 
 
 
 
 
 
 
 
 
77 
REFERENCES 
 
1. Woods SP, Moore DJ, Weber E, Grant I. Cognitive neuropsychology of HIV- 
 associated neurocognitive disorders. Neuropsychol Rev 2009; 19(2): 152-68.  
 
2. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC,  
 Collier AC, Evans SR, Ellis RJ. The prevalence and incidence of neurocognitive  
 impairment in the HAART era. AIDS 2007; 21(14): 1915-21.  
 
3. Simioni S, Cavassini M, Annoni JM, Abraham AR, Bourquin I, Schiffer V, Calmy A,  
 Chave JP, Giacobini E, Hirschel B, Du Pasquier RA. Cognitive dysfunction in  
 HIV patients despite long-standing suppression of viremia. AIDS 2010; 24(9):  
 1243-50. 
 
4. Gannon P, Khan MZ, Kolson DL. Current understanding of HIV-associated  
 neurocognitive disorders pathogenesis. Curr Opin Neurol 2011; 24(30): 275-83.  
 
5. Letendre S. Central nervous system complications in HIV disease: HIV-associated  
 neurocognitive disorder. Top Antivir Med 2011; 19(4): 137-42.  
 
6. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, McCuthchan JA,  
 Reicks C, Grant I, HNRC Group. The impact of HIV-associated  
 neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc  
 2004; 10(3): 317-31.  
 
7. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-  
 associated neurocognitive disorders mind the gap. Ann Neurol 2010; 67(6): 699- 
 714.  
 
8. Liu F, Dai S, Gordon J, Qin X. Complement and HIV-1 infection/ HIV-associated  
 neurocognitive disorders. J Neurovirol 2014; 20(2): 184-198.  
 
9. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AD, Cleary P. The brain in AIDS:  
 central nervous system HIV-1 Infection and AIDS dementia complex. Science  
 1988; 239(4840): 586-92.  
 
10. Cardenas VA, Meyerhoff DJ, Studholme C, Kornak J, Rothlind J, Lampiris H,  
 Neurhaus J, Grant RM. Evidence for ongoing brain injury in human  
 immunodeficiency virus- positive patients treated with antiretroviral therapy. J  
 Neurovirol 2009; 15(4): 324-33.  
 
11. Ances BM, Ellise RJ. Dementia and neurocognitive disorders due to HIV-1 infection.  
 Semin Neurol 2007; 27(1): 86-92.  
 
 
78 
 
12. Bell JE, Arango JC, Anthony IC. Neurobiology of multiple insupts: HIV-1  
 Associated Brain Disorders in Those Who Use Illicit Drugs. J Neuroimmune Phar  
 2006; 1(2): 182-91.  
 
13. Kennedy CA, Zerbo E. HIV-related neurocognitive disorders and drugs of abuse: 
 mired in confound, surrounded by risk. Curr Addict Rep 2014; 1: 229-36.  
 
14. Sacktor N, Skolasky R, Selnes OA, Watters M, Poff P, Shiramizu B, Shikuma C,  
 Valcour V. Neuropsychological test profile differences between young and old  
 human immunodeficiency virus-positive individuals. J Neurovirol 2007; 13(30):  
 203-9.  
 
15. Foley J, Ettenhofer M, Wright MJ, Siddiqi I, Choi M, Thames AD, Mason K,  
 Castellon S, Hinkin CH. Neurocognitive functioning in HIV-1 infection: effects  
 of cerebrovascular risk ractors and age. Clin Neuropsychol 2010; 24(2): 265-85.  
 
16. Thames AD, Foley JM, Panos SE, Singer EJ, El-Saden S, Hinkin CH. Cognitive  
 reserve masks neurobehavioral expression of human immunodeficiency virus- 
 associated neurological disorder in older patients. Neurobehavioral HIV Medicine  
 2011 3: 87-93.  
 
17. Patel SM, Thames A, Arbid N, Panos S, Castellon S, Hinkin C. The aggregate effects  
 of multiple comorbid risk factors on cognition among HIV-infected individuals. J  
 Clin Exp Neuropsychol 2013; 35(4): 421-43.  
 
18. Letendre S, Paulin AD, Rockenstein E, Adame A, Crews L, Cherner M, Heaton R,  
 Ellis R, Everall IP, Grant I, Masliah E, HIV Neurobehavioral Research Center  
 Group. Pathogenesis of hepatitis C virus coinfection in the brains of patients with  
 HIV. J Infect Dis 2007; 196(3): 361-70.  
 
19. Skalski LM, Sikkema KJ, Heckman TG, Meade CS. Coping styles and illicit drug use  
 in older adults with HIV/AIDS. Psychol Addict Behav 2013; 27(4): 1050-8.  
 
20. Green JE, Saveanu RV, Bornstein RA. The effect of previous alcohol abuse on  
 cognitive function in HIV infection. Am J Psychiat 2004; 161(2): 249-54.  
 
21. American Psychiatric Association. (2013). Diagnostic and statistical manual of  
 mental  disorders (5th ed.). Arlington, VA: American Psychiatric Publishing. 
 
22. Marin-Thormeyer EM, Paul RH. Drug abuse and hepatitis C infection as comorbid  
 features of HIV associated neurocognitive disorder: neurocognitive and  
 neuroimaging features. Neuropsychol Rev. 2009; 19(2): 215-31.  
 
 
 
79 
23. Fogarty A, Rawstorne P, Prestage G, Crawford J, Grierson J, Kippax S. Marijuana as  
 therapy for people living with HIV/AIDS: social and health aspects. AIDS Care 
 2007; 19(2): 295-301.  
 
24. Surah S, Kieran J, O’Dea S, Shiel C, Raffee S, Mulcahy F, Keenan E, Lyons F. Use  
 of the  alcohol use disorders identification test (AUDIT) to determine the  
 prevalence of alcohol  misuse among HIV-infected individuals. Int J STD AIDS  
 2013; 24(7): 517-21.  
 
25. Galvan FH, Bing EG, Fleishman JA, London As, Caetano R, Burnam MA, Longshore  
 D, Morton SC, Orlando M, Shapiro M. The prevalence of alcohol consumption  
 and heavy drinking among people with HIV in the united states: results from the  
 HIV cost and services utilization study. J Stud Alcohol 2002; 63(2): 179-86.  
 
26. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999; 58(4): 315- 
 48.  
 
27. Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and  
 neuropsychological performance. Neuropsychol Rev 2007; 17(3): 347-61.  
 
28. Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term  
 effect of cannabis use on executive cognitive functions. J Addict Med 2011; 5(1):  
 1-8.  
 
29. Lundqvist T. Cognitive consequences of cannabis use: comparison with abuse of  
 stimulants and heroin with regard to attention, memory and executive functions.  
 Pharmacol Biochem Be 2005; 81(2): 319-30.  
 
30. Chang L, Yakupov R, Cloak C, Ernst T. Marijuana use is associated with a  
 reorganized visual-attention network and cerebellar hypoactivation. Brain 2006;  
 129(Pt5): 1096-112.  
 
31. Rantanathan M, D’Souza DC. The acute effects of cannabinoids on memory in  
 human: a review. Psychopharmacology (Berl) 2006; 188(4): 425-44.  
 
32. Kelleher LM, Stough C, Sergejew AA, Rolfe T. The effects of cannabis on  
 information-processing speed. Addict Behav 2004; 29(6): 1213-9.  
 
33. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schnieder E, Moeller  
 MR. High-potency marijuana impairs executive function and inhibitory motor  
 control. Neuropsychopharmacology 2006; 31(10): 2296-303.  
 
34. Hart CL, van Gorp W, Haney M, Foltin RW, Fischman MW. Efects of acute smoked  
marijuana on complex cognitive performance. Neuropsychopharmacology 2001;  
 
 
80 
25(5): 757-65.  
 
35. Curan HV, Brignell C, Fletcher S, Middleton P, Henry J. Cognitive and subjective  
 dose-response effects of acute oral delta 9-tetrahydrocannabinol (THC) in  
 infrequent cannabis users. Psychopharmacology (Berl) 2002; 164(1): 61-70.  
 
36. O’Leary DS, Block RI, Turner BM, Koeppel J, Magnotta VA, Ponto LB, Watkins  
 GL, Hickwa RD, Andreasen NC. Marijuana alters the human cerebellar clock.  
 Neuroreport 2003; 14(8): 1145-51.  
 
37. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms  
 following smoked marijuana in humans. Psychopharmacology (Berl) 1999;  
 141(4): 395-404.  
 
38. Budney AJ, Hugues JR, Moore BA, Vandrey R. Review of the validity and  
 significance of cannabis withdrawal syndrome. Am J Psychiatry 2004; 161(11):  
 1967-77.  
 
39. Pope HG Jr, Gruber AJ, Yurgelun-Todd D. The residual neuropsychological effects  
 of cannabis: the current status of research. Drug Alcohol Depend 1995; 38(1): 25- 
 34.  
 
40. Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive  
 performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharm 
 2012; 20(5): 420-9.  
 
41. Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Non-acute (residual)  
neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol 
Soc 2003; 9(5): 679-89.  
 
42. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D.  
 Neuropsychological performance in long-term cannabis users. Arch Gen Psychiat  
 2001. 58(10): 909-15.  
 
43. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Cognitive  
 measures in long-term cannabis users. J Clin Pharmacol 2002; 42(11 Suppl):  
 41S-47S.  
 
44. Battisti RA, Roodenrys S, Johnstone SJ, Pesa N, Hermens DF, Solowij N. Chronic  
 cannabis users show altered neurophysiological functioning on stroop task  
 conflict resolution. Psychopharmacology (Berl) 2010; 212(4): 613-24.  
 
45. Battisti RA, Roodenrys S, Johnstone SJ, Respondek C, Hermens DF, Solowij N.  
 Chronic use of cannabis and poor neural efficiency in verbal memory ability.  
 
 
81 
 Psychopharmacology (Berl) 2010; 209(4): 319-30.  
 
46. Block RI, O’Leary DS, Hichwa RD, Augustinack JC, Boles Ponto LL, Ghoneim MM,  
 Arndt S, Hurtig RR, Watkins GL, Nathan PE, Andreasen NC. Effects of frequent  
 marijuana use on memory-related regional cerebral blood flow. Pharmacol  
 Biochem Behav 2002; 72(1- 2): 237-50.  
 
47. Kanayama G, Rogowska J, Pope HG, Gruber SA, Yurgelun-Todd Da. Spatial  
 working memory in heavy cannabis users: a functional magnetic resonance  
 imaging study. Psychopharmacology (Berl) 2004; 176(3-4): 239-47.  
 
48. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen  
 K, McRee B, Vandetti J, Marijuana Treatment Project Research Group. Cognitive  
 functioning of long-term heavy cannabis users seeking treatment. JAMA 2002;  
 287(9): 1123-31.  
 
49. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects  
 of marijuana use. Neurology 2002; 59(9): 1337-43.  
 
50. Fisk JE, Montgomery C. Real-world memory and executive processes in cannabis  
 users and non-users. J Psychopharmacol 2008; 22(7): 727-36.  
 
51. Jager G, Kahn RS, Van Den Brink W, Van Ree JK, Ramsey NF. Long-term effects of 
 frequent cannabis use on working memory and attention: an fMRI study. 
 Psychopharmacology (Berl) 2006; 185(3): 358-68.  
52. Chang L, Cloak C, Yakupov R, Ernst T. Combined and independent effects of  
 chronic marijuana use and HIV on brain metabolites. J Neuroimmune Pharmacol  
 (2006); 1(1): 65-76.  
 
53. Ridley NJ, Draper B, Withall A. Alcohol-related dementia: an update of the evidence.  
 Alzheimers Res Ther 2013; 5(1):3.  
 
54. Moselhy HF, Georgiou G, Kahn A. Frontal lobe changes in alcoholism: a review of  
 the literature. Alcohol 2001; 36(5):357-68.  
 
55. Harper C, Matsumoto I. Ethanol and brain damage. Curr Opin Pharmacol 2005;  
 5(1):73-8.  
 
56. Harris RA, Trudell JR, Mihic SJ. Ethanol’s moledular targets. Sci Signal 2008;  
 1(28):re7.  
 
57. Lallemand F, Ward RJ, Witte PD, Petit G, Saeremans M, Verbanck P, Noel X,  
 Campanella  
 
 
82 
 S. Changes in the innate immune responses by intermittent ethanol consumption  
 may influence cognition in susceptible adolescent binge drinkers. J Alcoholism  
 Drug Depend 2013; 1(3): 114.  
 
58. Zhao YN, Want F, Fan YX, Ping GF, Yang JY, Wu CF. Activated microglia are  
 implicated in cognitive deficits, neuronal death, and successful recovery  
 following intermittent ethanol exposure. Behav Brain Res 2013; 236(1): 270-82.  
 
59. He J, Crews FT. Increased MCP-1 and microglia in various regions of the human  
 alcoholic brain. Exp Neurol 2008; 210(2): 349-58.  
 
60. Weissenborn R, Duka T. Acute alcohol effects on cognitive function in social  
 drinkers: their relationship to drinking habits. Psychopharmacology (Berl) 2003;  
 165(3): 306-12.  
 
61. Townshend JM, Duka T. Bing drinking, cognitive performance, and mood in a  
 population of young, social drinkers. Alcohol Clin Exp Res 2005; 29(3): 317-25.  
 
62. Stephens DN, Duka T. Review. Cognitive and emotional consequences of binge  
 drinking: a role of amygdala and prefrontal cortex. Philos Trans R Soc Lond B  
 Biol Sci 2008;  363(1507): 3169-79.  
 
63. Loeber S, Duka T, Welzel H, Nakovics H, Heinz A, Flor H, Mann K. Impairment of  
 cognitive abilities and decision making after chronic use of alcohol: the impact of  
 multiple detoxifications. Alcohol Alcohol 2009; 44(4): 372-81.  
 
64. Kril JJ, Halliday GM, Svoboda MD, Cartwright H. The cerebral cortex is damaged in  
 chronic alcoholics. Neuroscience 1997; 79(4):983-98.  
 
65. Fein G, Torres J, Price LJ, Di Sclafani V. Cognitive performance in long-term  
 abstinent alcoholic individuals. Alcohol Clin Exp Res 2006; 30(9):1538-44.  
 
66. Duka T, Townshend JM, Collier K, Stephens DN. Impairment in cognitive functions 
 after multiple detoxifications in alcoholic inpatients. Alcohol Clin Exp Res 2003;  
27(10):1563-72.  
 
67. Parson OA. Neurocognitive deficits in alcoholics and social drinkers: a continuum?  
 Alcohol Clin Exp Res 1998; 22(4): 954-61.   
 
68. Scott-Sheldon LA, Walstrom P, Carey KB, Johnson BT, Carey MP, MASH Research  
 Team. Alcohol use and sexual risk behaviors among individuals infected with  
 HIV: a systemic review and meta-analysis 2012 to early 2013. Curr HIV/AID Rep 
 2013; 10(4): 314-23.  
 
 
 
83 
69. Longmire-Avital B, Holder CA, Golub SA, Parsons JT. Risk factors for drinking  
 among HIV-positive african american adults: the depression-gender interaction.  
 Am J Drug Alcohol Ab 2012; 38(3): 260-6.  
 
70. Elliott JC, Aharonovich E, O’Leary A, Wainberg M, Hasin DS. Drinking motives  
 among  HIV primary care patients. AIDS Behav 2014; 8(7): 1315-23.  
 
71. Braithwaite RS, Conigliaro J, Robers MS, Shechter S, Schaefer A, McGinnis K,  
 Rodriguez MC, Rabeneck L, Bryant K, Justice AC. Estimating the impact of  
 alcohol consumption on survival for HIV+ inividuals. AIDS Care 2007;  
 19(4):459-66.  
 
72. Rothlind JC, Greenfield TM, Bruce AV, Meyerhoff DJ, Flenniken DL, Lindgren JA,  
 Weiner MW. Heavy alcohol consumption in individuals with HIV infection:  
 effects on neuropsychological performance. J Int Neuropsychol Soci 2005; 11(1):  
 70-83.  
 
73. Chandler G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non- 
 adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr  
 2006; 43(4): 411-7.  
 
74. Heinz AJ, Folger KA, Newcomb ME, Trafton JA, Bon-Miller MO. Problematic  
 alcohol use among individuals with HIV: relations with everyday memory  
 functioning and symptom severity. AIDS Behav 2014; 18(7): 1302-14.  
 
75. Green JE, Saveanu RV, Bornstein RA. The effect of previous alcohol abuse on  
 cognitive function in HIV infection. Am J Psychiatry 2004; 161(2): 249-54.  
 
76. Selnes OA. Impact of HIV infection and alcohol on cognition: a review.  
 Neurobehavioral HIV Medicine 2010; 2010(2): 85-94.  
 
78. Fama R, Rosenbloom MJ, Sassoon SA, Thompson MA, Pfefferbaum A, Sullivan EV. 
 Remote semantic memory for public figures in HIV infection, alcoholism, and  
 their  comorbidity. Alcohol Clin Exp Res 2011; 35(2): 265-76. 
 
79. Sassoon SA, Fama R, Rosenbloom MJ, O’Reilly A, Pfefferbaum A, Sullivan EV. 
 Component cognitive and motor processes of the digit symbol test: differential  
 deficits in alcoholism, HIV infection, and their comorbidity. Alcohol Clin Exp Res  
 2007; 31(8): 1315-24.  
 
80. Schulte T, Mueller-Oehring EM, Rosenbloom MJ, Pfefferbaum A, Sullivan EV.  
 Diffrential effect of HIV infection and alcoholism on conflict processing,  
 attentional allocation, and perceptual load: evidence from a stroop match-to- 
 sample task. Biol Psychiat 2005; 57(1):67-75.  
 
 
84 
81. Fein G, Fletcher DJ, Di Sclafani V. Effect of chronic alcohol abuse on the CNS  
 morbidity of HIV disease. Alcohol Clin Exp Res 1998; 22(5 Suppl): 196S-200S.  
 
82. Meyerhoff DJ. Effects of alcohol and HIV infection on the central nervous system.  
 Alcohol Res Health 2001; 25(4): 288-98.  
 
83. Pfefferbaum A, Rosenbloom MJ, Rohlfing T, Adalsteinsson E, Kemper CA,  
 Deresinski S, Sullivan EV. Contribution of alcoholism to brain dysmorphology in  
 HIV infection: effects on the ventricles and corpus collosum. Neuroimage 2006;  
 33(1):239-51.  
 
84. Pfefferbaum A, Rosenbloom MJ, Adalsteinsson E, Sullivan EV. Diffusion tensor 
 imaging with quantitative fibre tracking in HIV infection and alcoholism  
comorbidity: synergistic white matter damage. Brain 2007; 130(Pt 1): 48-64.  
 
85. Fiellin DA, McGinnis KA, Maisto SA, Justice AC, Bryant K. Measuring alcohol  
 consumption using timeline followback in non-treatment-seeking medical clinic 
patients with HIV infection: 7-, 14-, or 30-day recall. J Study Alcohol Drugs  
2013; 74(3): 500-4.  
 
86. Hasbun R, Eraso J, Ramireddy S, Wainwright A, Salazar L, Grimes R, York M, Strutt  
 A. Screening for Neurocognitive impairment in HIV individuals: the utility of the  
 montreal cognitive assessment test. J AIDS Clinic Res 2013; 3(10): 186.  
 
87. Lam B, Middleton LE, Masellis M, Stuss DT, Harry RD, Kiss A, Black SE. Criterion  
 and convergent validity of the montreal cognitive assessment with screening and  
 standardized neuropsychological testing. J Am Geriatr Soc 2013; 61(12): 2185-5.  
 
88. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and  
usefulness of the medical outcomes study HIV health survey (MOS-HIV). Qual 
Life Res  1997; 6(6): 481-93.  
 
89. Richardson JL, Heikes B, Karim R, Weber K, Anastos K, Young M. Experience of  
pain among women with advanced HIV disease. AIDS Patient Care ST 2009; 
23(7): 503-11.  
 
90. Cristiani SA, Pukay-Marin ND, Bornstein RA. Marijuana use and cognitive function  
 in HIV-infected people. J Neuropsychiatry Clin Neurosci  2004; 16(3):330-5.  
 
91. Global AIDS overview (2014). Retrieved January 25th, 2015, from aids.gov: 
 http://www.aids.gov/federal-resources/around-the-world/global-aids-overview 
92. HIV/AIDS fact sheets (2014). Retrieved January 21st, 2015 from cdc.gov: 
 http://www.cdc.gov/hiv/library/factsheet/index_html  
 
 
85 
93. Marijuana resource center: state laws related to marijuana (2014). Retrieved January  
25th, 2015 from whitehouse.gov: http://www.whitehouse.gov/ondcp/state-laws-
related-to-marijuana 
 
94. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity:  
 a critical review of available methods. J Clin Epidemiol (2003); 56(3): 221-9.  
 
95. Charlson ME, Pompei P, Alex KL, MacKenzie CR. A new method of classifying 
 prognostic comorbidity in longitudinal studies: development and validation. J 
 Chron Dis (1987);  40(5): 373-83.  
 
96. Kroenke K, Spitzer RL, Williams JB. The patient health qustionnaire-2: validity of a  
 2-item  depression screener. Med Care (2008); 41(11): 1284-92.  
 
97. Norman SB, Campbell-Sills L, Hitchcock CA, Sullivan S, Rochlin A, Wilkins KC,  
 Stein  MB. Psychometrics of a brief measure of anxiety to detect severity and  
 impairment: the overall anxiety severity and impairment scale (OASIS). J  
 Psychiatr Res (2011); 45(2):  262-8.  
 
98. Norman SB, Hami-Cissell S, Means-Christensen AJ, Stein MB. Development and  
 validation of an overall anxiety severity and impairment scale (OASIS). Depress  
 and Anxiety  (2006); 23: 245-9.  
 
99. Leonhard C, Mulvey K, Gastfriend DR, Shwartz M. Addiction severity index: a field  
 study of internal consistency and validity. J Subst Abuse Treat (2000); 18(2): 129- 
 35.  
 
100. McLellan AT, Cacciola JC, Alterman AI, Rikoon JH, Carise D. The addiction  
 severity index at 25: origins, contributions and transitions. Am J Addict (2006);  
 15(2): 113-24.  
 
101. Ridley MJ, Draper B, Withall A. Alcohol-related dementia: an update of the  
 evidence. Alzheimers Res Ther (2013); 5(1): 3.  
 
102. Skinner HA, Sheil WJ. Reliability of alcohol use indices the lifetime drinking  
 history and the MAST. J Stud Alcohol (1982); 43(11): 1157-70.  
 
103. Jacob T, Seilhamer RA, Bargeil K, Howell DN. Reliability of lifetime drinking  
 history among alcohol dependent men. Psychol Addict Behav (2006); 20(3): 333- 
 7.  
 
104. Jonsdoltir MK, Sigurdsson S, Harris TB, Gudnason V, Launir LJ. The alcohol  
 paradox: light to moderate alcohol consumption, cognitive function, and brain  
 volume. J Gerontol A Biol (2014); 69(12): 1528-35.  
 
 
86 
105. Collins MA, Neafsey EJ, Mukamal KJ, Gray MO, Parks DA, Das DK, Korthuis RJ. 
 Alcohol in moderation, cardioprotection, and neuroprotection: epidemiological 
 considerations and mechanistic studies. Alcohol Clin Exp Res (2009); 33(2): 206- 
 19.  
 
106. Ganguli M, Vander Bilt J, Saxton JA, Stien C, Dodge HH. Alcohol Consumption  
 and cognitive function in late life: a longitudinal community study. Neurology  
 (2005); 65(8):  1210-7.  
 
107. Leroi I, Sheppard JM, Lyketsos CG. Cognitive function after 11.5 years of alcohol  
 use: relation to alcohol use. Am J Epidemiol (2002); 156(8); 747-52.  
 
108. Bartley PC, Rezvani AH. Alcohol and cognition- consideration of age of initiation,  
 usage  patterns and gender: a brief review. Curr Drug Abuse Rev (2012); 5(2):  
 87-97.  
 
109. Parsons OA, Nixon SJ. Cognitive functioning in sober social drinkers: a review of  
 research since 1986. J Study Alcohol (1998); 59(2): 180-90.  
 
  
 
 
87 
CURRICULUM VITAE 
SARA LORKIEWICZ 
Born: 1990 
3 Hollis Place, Apt 2 Allston, MA 02134 
Phone: 708-989-8621 
Email: s.lorkiewicz1@gmail.com 
 
 
Education:  
2013 – Present  Boston University School of Medicine 
Pursuing an M.S. in Medical Sciences  
Relevant Courses Completed:  
 Medical Physiology, Biochemistry, Intro to Pathology, Intro to Neuroscience 
 
2008- 2012    Loyola University Chicago  
B.S. in Molecular Biology  
B.S. in Psychology 
Relevant Courses Completed:  
 Brain and Behavior, Cognitive Psychology, Abnormal Psychology, Research Methods, 
Molecular Genetics, Immunology 
 
Research Experience:  
 
Thesis work with Dr. Richard Saitz- Boston University School of Public Health, Boston, 
MA 
- June 2014 – present  
- Master’s Student in the MAMS program at Boston University School of Medicine 
- Researching the association of marijuana, alcohol, and cognitive dysfunction in 
patients with HIV/AIDS using data from the BOSTON ARCH cohort.  
 
 Molecular Genetics lab with Dr. Eric Schroeter - Loyola University Chicago, Chicago, 
IL 
- January – May 2011    
- Assisted graduate students and Dr. Schroeter in studying how specific neurons make 
synaptic connections in the retina through various molecular biology techniques such 
as PCR, gel electrophoresis, florescence in situ hybridization 
   
  Social psychology research lab with Dr. Fred Bryant – Loyola University Chicago, 
Chicago IL 
- August – December 2009    
 
 
88 
- Assisted graduate students and Dr. Bryant in studying the effects of positive and 
negative emotions on gratitude through proctoring surveys which student 
participants took and inputing data into SPSS.  
 
   
Volunteering Experience: 
  bWell Center – Boston Medical Center, Boston, MA 
- May 2014 – Present    
- Our aim is to promote health and wellness through fun, educational activities with 
children and their parents who are being seen in the pediatrics department       
 
  Northwestern Rehabilitation Institute of Chicago – Northwestern University Chicago, 
Chicago, IL 
- November 2011 – May 2012    
- Assisted physical therapists in an in-patient setting with group therapy sessions to 
help rehabilitate patients with a wide range of histories including car accidents, 
surgeries, and broken bones.     
  
  Loyola EMS – Loyola University Chicago Chicago IL 
- November 2010 – May 2012  
- Responded to emergency situations of students on Loyola University's campus as 
well as took part in training new EMT students in the program  
 
  Global Medical Brigades – Loyola University Chicago, Chicago IL 
- November 2010 – August 2011    
- Traveled to Honduras, helping to prepare and set up medical clinics which offered 
free health care to the citizens of the rural towns we traveled to.     
